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Abstract: ∆9-tetrahydrocannabinol (∆9-THC) is an active component of
marijuana. During recent years, the popularity of marijuana in the United States has
increased tremendously. Marijuana edibles are a form of marijuana that has become very
popular in recent years. These are easily accessible not only to adolescents but also to
young children. According to recent statistical data, the consumption of marijuana edibles
by children below the age of 5 has increased 600% in the states that have legalized
marijuana. This has led to an adverse impact on children’s health as evidenced by a
sudden increase in the number of children seeking emergency assistance in hospitals. In
the current research, we addressed the issue of possible persistent effects on children’s
behavior due to an earlier exposure to ∆9-THC. Juvenile rats were treated with 10 mg/kg
of ∆9-THC from postnatal day 10 through 16. Once they reached adolescence, these rats
were tested using several behavioral paradigms. To evaluate the biological basis for the
behavioral deficits observed, brain samples obtained from these rats were subjected to
proteomic analysis to determine any altered pathways related to the behavior. Our
behavioral data indicated that juvenile exposure to ∆9-THC has no effect on anxiety-

related behavior in adolescents. However, we observed a significant effect of treatment
on multiple parameters related to social interactions. Of these, episodes and time of social
play were significantly increased in the ∆9-THC treated rats suggesting alterations in the
reward circuit function occurring as a result of developmental ∆9-THC exposure. In the
proteomics, we observed a significant effect on relevant canonical pathways such as the
changes in thrombin and opioid signaling. Thrombin signaling in neurons is associated
with processes involved in the connection between neurons and opioid signaling is
involved in the activation processes of the reward circuit suggesting that juvenile ∆9THC exposure alters these processes in adolescence which could have detrimental effects
on behavior. Overall, our data suggest that consumption of edibles by juveniles leads to
altered behavioral and biochemical outcomes in adolescence. This may be detrimental in
terms of the appropriate acquisition of skills necessary for meeting the challenges in
future life.
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DELTA9-TETRAHYDROCANNABINOL: MOLECULAR TARGETS, EFFECTS ON
EMOTIONAL AND SOCIAL BEHAVIOR AND INCREASING EXPOSURE
THROUGH MARIJUANA EDIBLES.
1.1

Background

Marijuana refers to the dried leaves, flowers, seeds or stems of plants known as Cannabis
sativa or Cannabis indica. Marijuana resins can be obtained from these plants in the form
of hash oil, wax, budder, or shatter which are widely smoked by the adolescent and adult
population in order to get ‘high’ (NIDA: Marijuana facts 2017). Even though marijuana is
currently among the most widely used illicit drug, it has been historically used for many
commercial and medicinal purposes. Marijuana plants were commonly grown in the 17th
century for the production of rope, sails and clothing. The medical applications for
marijuana originated from Chinese folk medicine that included the use of marijuana for a
variety of treatments as early as the 27th century BC (McKenna 2014). In the United States,
the use of marijuana for medical and recreational purposes increased in the early 19th
century and marijuana was an active ingredient in more than 20 drugs. During the same
period, the prohibitionist attitudes towards drugs was increasing and marijuana was
perceived as a dangerous drug able to induce sudden violent and murderous actions in
intoxicated individuals (Carliner et al., 2017). In 1937, the federal Marijuana Tax Act was
1

passed which prohibited the use of marijuana for recreational purposes. Since this law did
not ban medical uses, marijuana continued to be used for medicinal purposes under this
act. However, this law discouraged the use of marijuana for medical purposes by placing
the burden of detailed reporting on physicians who were in favor of prescribing marijuana
(McKenna 2014). According to the Control Substance Act of 1970, the United States Drug
Enforcement Administration (DEA) categorized marijuana as schedule 1 drug (i.e. a drug
with no medical application and high potential of abuse). This categorization made both
recreational and medical use of marijuana illegal. Despite the federal stance against
marijuana use, many Americans are in favor of marijuana being used for medical purposes.
Owing to the favorable attitude of public towards marijuana, states across the nation have
been eliminating the legal restrictions against marijuana. California was the first state to
allow marijuana for medical uses in 1996. Following that, more states allowed marijuana
for medical purposes. These changes have had consistent public support due to the
inclination of the majority of the population to live in jurisdictions where marijuana is legal.
By 2017, 28 states have legalized marijuana for medical purposes and 7 of them allow
recreational use as well (Carliner et al., 2017; Murphy and Carnevale 2016).
While legalization has alleviated the restrictions against using marijuana for medical
purposes, it has also increased voluntarily self-intoxication among adolescents (Hopfer
2014). This increase in self-intoxication can be attributed not only to the increased ease of
availability but also to the positive or permissible attitudes and diminished perception of
marijuana-associated risks of adolescents (Walker et al., 2017). Adolescents appear to be
unaware of the neurological and/or psychotic problems associated with the early-onset use
of marijuana as reported by number of studies. According to the Diagnostic and Statistical
2

Manual of Mental Disorders, 4th edition (DSM-IV), abuse and dependence are two major
problems associated with marijuana and account for 75-80% of total marijuana use disorder
cases. In a statistical study, marijuana abuse and dependence cases among the US adult
population occurring during 1991-1992 were compared with those occurring during 20012002. There was a significant increase in the level of abuse and dependence cases in the
latter period despite no significant increase in marijuana use among the adult population.
However, the comparatively higher potency of marijuana available in the latter period
might be an additional factor in the increased level of disorders (Compton et al., 2004).
Another consequence of marijuana legalization has been an increase in the popularity of
marijuana among school children. A study in Monitor the Future (MTF) reported that
marijuana smoking has been a common practice among 12th graders but since the mid1990s, it has become increasingly popular among 10th graders and 8th graders because of
the lowered perceived risk and increase in the ease of availability during that period (MTF
2015).
Early onset of marijuana use is associated with certain structural abnormalities in the brain
that eventually lead to behavioral deficits. Neuronal pruning is one of the essential
processes by which the developing brain forms into a mature brain by establishing proper
connections across the brain regions. Disrupted pruning can lead to mental disorders such
as autism, schizophrenia, depression and others (Boksa 2012). Neuroimaging studies have
reported that neuronal pruning can be drastically affected in cannabis users (Filbey et al.,
2015). In addition to neuronal pruning, heavy cannabis consumption is also related to a
reduction in the area of white matter that is associated with increased impulsivity (Gruber
et al., 2014), and increased activity in cortical areas that is associated with attention
3

difficulties (Abdullaev et al., 2010). Currently, the available literature is limited to
addressing the adverse effects of marijuana use in adolescents. Despite the documented
increase in the availability of and exposure to marijuana in children, there have been no
studies that have addressed the long-term effects of marijuana exposure in children.
Edible marijuana is one of the choice methods for marijuana intake along with smoking
and vaping. Starting in 2014, Colorado allowed the commercial production of edible
marijuana and marijuana is now available in a form that mimics popular candies or sweets.
These products can be legally purchased in retail stores in four states; Colorado,
Washington State, Alaska, and Oregon (MacCoune et al., 2015). In California, marijuana
edibles are available in dispensaries but only those who possess a medical marijuana card
which can be obtained by anyone including those below 18 years as long as they are under
a parent’s supervision (Borodovsky et al., 2016). According to sales (NIDA 2014) and
social networking surveys (Borodovsky et al., 2016; Lamy et al., 2016), the popularity of
marijuana edible products is increasing in states with legalized marijuana as compared to
non-legalized states. This has created serious health concerns because of the enhanced risk
of edible marijuana being consumed by children even though current laws restrict
recreational marijuana use to those under the age of 21 (MacCoun et al., 2015). In addition,
the packaging of these edibles in bright colors is more likely to attract children who are
unaware of the risk. This ‘child friendly’ packaging is increasing either deliberate or
unintentional consumption of marijuana among children and there has been increased
reports of cases of childhood intoxication especially in states with legalized marijuana
(MacCoun et al., 2015). The data from poison control centers indicates higher rates of
emergency calls and an increase in the number of patients seeking care at children’s
4

hospitals in states with legalized marijuana because of the unintentional ingestion of
marijuana in children of age below 9. Soon after the commercialization of marijuana
edibles in Colorado in 2014, there was 70% increase in the calls related to marijuana
exposure compared to the prior year (Ghosh et al., 2013). In another study conducted at a
tertiary-care children’s hospital in Colorado, there were 14 cases, all below the age of 12,
that involved intoxication related to marijuana ingestion during 2009-2011 as compared to
none during 2005-2009 (Wang et al., 2013). Marijuana edibles were originally introduced
for medical purpose and meant for medical-prescribing to those who are not comfortable
with smoking marijuana or children who can take them under caregiver’s supervision.
However, this has led to unintentional unwanted childhood exposure.
The main psychoactive component of marijuana is ∆9-tetrahydrocannabinol commonly
known as ∆9-THC. When marijuana is consumed through any route of exposure, the
concentration of ∆9-THC increases in the blood and is mainly responsible for the
marijuana-related effects (NIDA 2017). ∆9-THC was first isolated in 1964 (Gaoni and
Mechoulam 1964) and has been frequently studied for its pharmacological and
psychoactive effects. In rodents, ∆9-THC is known to produce myriad of behavioral effects
of which the most common ones are catalepsy, analgesia, hypothermia and
hypolocomotion. These effects are commonly known as ‘tetrad model’ of cannabimimetic
activity (Martin et al., 1991). Catalepsy is muscular rigidity or fixity of posture regardless
of external stimuli. Several studies reported that ∆9-THC could induce catalepsy in rodent
models by using bar catalepsy test (Marchese et al., 2003; Monory et al., 2007; Sano et al.,
2008). Analgesia is reduced response to painful stimuli and has been detected following
∆9-THC exposure by measuring reaction time using the hot plate analgesia test (Monory
5

et al., 2007) or the tail-flick latency test (Fuentes et al., 1999). Similarly, ∆9-THC exposure
is also associated with reductions in body temperature and locomotor activity as detected
by measuring the rectal temperature and performance in the open field test, respectively
(Monory et al., 2007).
To relate the route of exposure and the change in ∆9-THC levels in the blood, Lemberger
and colleagues (1972) compared the plasma concentration of ∆9-THC following
intravenous, ingestion, or inhalation administration of marijuana. The plasma ∆9-THC
level was at its peak 70 min following inhalation and 3 hours following ingestion. Ingestion
could be more dangerous route of exposure because of increased ∆9-THC bioavailability
since it does not require combustion, which is the case for inhalation. Around 50% of ∆9THC is lost in the burning process and the amount of uptake of the remainder depends upon
the lung capacity and the amount of time that the smoker retains the smoke inside the lungs
before exhalation (Elzinga et al., 2015). The onset of effects is rapid following inhalation.
However, the onset of effects following ingestion is much slower than smoking because of
delay of entrance of ∆9-THC into the blood stream. This factor is a prominent cause of
marijuana-related overdoses because of the misinterpretation that initial dose did not
induce the desired effect and the continued intake of more of the edible marijuana product
(Brodovsky et al., 2016).
The ∆9-THC content in marijuana edibles is another major concern that could be related
to the increase in intoxications. Over the time course of marijuana legalization, the ∆9THC content in the products has increased to more than 20% from 15% (Ghosh et al.,
2015). Often, underestimation of the ∆9-THC content on labeling is worsening this
6

problem. In a sample of 75 marijuana edibles collected from four different states, more
than half of these edibles contained a label that underestimated the ∆9-THC content of the
product (Vandrey et al., 2015). This could be a significant contributor towards overdose.
The ∆9-THC content of marijuana edibles are calculated by number of ∆9-THC servings
present in the edibles. Considering the increasing intoxication cases related to ∆9-THC
ingestion, states that allow edible sales are implementing the restrictions on the amount of
∆9-THC in each serving. ∆9-THC content is set to be 10 mg/serving in Colorado and
Washington State (MacCoun et al., 2015), and 5 mg/serving in Alaska and Oregon
(Gourdet et al., 2017). However, there is not a policy that instructs manufacturer to limit
the number of servings in each edible or to include on the label, the maximum daily intake
of number of servings and/or edibles (Ghosh et al., 2015).
The primary target of ∆9-THC in the brain is the type I cannabinoid receptors (CB1;
Devane 1988; Belue et al., 1994) which is a component of the endocannabinoid system.
Most of the behavioral effects induced by ∆9-THC in laboratory studies are due to its action
on CB1 receptors. The behavioral effects induced by ∆9-THC are because of its detrimental
effects on developing neurons. Tyrosine Hydroxylase (TH) is an enzyme responsible for
maturation of developing dopaminergic neurons (Fernandez-Ruiz et al., 1999). Gestational
exposure to ∆9-THC has been reported to reduce the mRNA level of TH during the
gestational period (Bonin et al., 1995), the postnatal/juvenile period, and the adult stage of
life in rats (Suarez et al., 2000). Cholecystokonin is involved in the growth cone formation
and axonal migration in developing neurons and prenatal ∆9-THC exposure reduces the
density of cholecystokonin containing interneurons in hippocampus of juvenile rats
(Vargish et al., 2017). Synapsin is a synaptic protein present in the axonal terminal and
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important in establishing synaptic functions and exposure to ∆9-THC is associated with
reduction in the mRNA levels of synapsin and CB1 receptor in adolescent rats (Steel et al.,
2011). Exposure to ∆9-THC during adolescence is also related to hypofunction of GABA
neurotransmission in prefrontal cortex of adult rats and this decrease in GABA
neurotransmission was accompanied by an increase in the dopaminergic neurotransmission
in ventral tegmental area (Renard et al., 2017).
1.2

The Endocannabinoid System

The endocannabinoids are a group of neuro-modulatory lipids involved in a variety of
physiological processes such as appetite, mood, sensation, and memory. These are not
stored in vesicles but are produced through an on-demand basis when neurons are in
excited state. This excitation of neurons leads to increase in intracellular calcium. The
increase in intracellular calcium activates calcium-dependent N-acetyl transferase (NAT)
which catalyzes the rate limiting step in the production of anandamide (Kano et al., 2009).
This leads to increased production of the endocannabinoids that are then released from
neurons and bind to the CB1 receptors (Lutz 2004). The mechanism by which the
endocannabinoids exert their function was described by Alger and Marty (2001) who
studied cerebellar purkinje neurons and hippocampal neurons. They observed that
depolarization in the postsynaptic GABA cell leads to release of retrograde messengers
that travel to presynaptic locus to suppress the release of neurotransmitter in that neuron.
They called it “depolarization induced suppression of inhibition” or DSI.

They also

observed that this retrograde messenger was performing an analogous function in
glutamatergic neurons by inhibition of excitation which they called as “depolarization
induced suppression of excitation” or DSE. Both DSI and DSE can be blocked by CB1
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receptor antagonists and enhanced by CB1 agonists indicating that the retrograde
messenger inducing DSE and DSI is an endogenous cannabinoid or an endocannabinoid
(Alger 2004). There are two main endogenous lipids, which bind to the CB1 receptors that
are Arachidonoyl ethanolamine or Anandamide (AEA), and 2-Arachidonoyl glycerol (2AG). These are produced in the postsynaptic neuron, cross the synapse, and stimulate CB1
receptors that are present on the presynaptic neuronal membrane. After stimulating the
CB1 receptor, these lipids are taken up into the neurons through specific reuptake
transporters and then degraded. The enzymes fatty acid amid hydrolase (FAAH) degrades
anandamide and monoacylglycerol lipase (MAGL) degrades 2-AG (Kano et al., 2009).
1.2.1

Functions of CB1 receptors in developing brain

Being a part of the endocannabinoid system, the CB1 receptor plays a vital role in brain
development. Receptor dimerization is a critical phenomenon during neuronal
development. Diverse receptors, such as the neurotrophic and growth factor receptors, are
recruited to the CB1 receptor which implicates a role for the CB1 receptor in neuronal
development (Harkany et al., 2008). Gestational day (GD) 11-14 is an important period in
rats because this is the period where formation of the neural tube from ectodermal cells
occurs. The brain and spinal cord are subsequently differentiated from the neural tube
(Semple et al., 2013). CB1 mRNA is detected during this period suggesting that the
cannabinoid receptors are important for these developmental processes. In addition to
presence of CB1 mRNA, an increase in GTP-binding protein occurs in the presence of a
cannabinoid agonist. This GTP-binding was mainly observed during the gestational period
in brain regions where the CB1 receptors are scarcely distributed or practically absent in
the adult brain. These brain regions are enriched in neuronal fibers and include white
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matter areas of the midbrain and brainstem (Romero et al., 1997). Later, it was reported
that in white matter areas, the CB1 receptors are located in the migrating axons whose cell
bodies are located at significant distance from the site of the functioning receptor. This
emphasizes the role of CB1 receptor in synaptogenesis (Fernandez-Ruiz et al., 2000). This
role is also supported by the fact that the expression of the CB1 receptor is positively
correlated with expression of Brain Derived Neurotropic Factor (BDNF), which is involved
in axonal growth and migration during development (Maison et al., 2009).
Other studies have observed that activation of CB1 receptors by external cannabinoids
during pregnancy can be detrimental to key proteins involved the brain development.
Neural cell adhesion molecule (L1) is responsible for cell-cell and cell-matrix interactions
allowing proteins to perform their functions such as cell proliferation, migration,
synaptogenesis, and myelin formation. Mutation in the L1 genes leads to malformation of
brain. Activation of the CB1 receptors by ∆9-THC exposure during pregnancy resulted in
down regulation of genes responsible for L1 in rat brain during the fetal (Gomes et al.,
2003) and early postnatal period (Gomes et al., 2007).
Irregular activation of CB1 receptors leading to abnormalities in the brain development is
not only restricted to fetal period. Activation of the CB1 receptors as a result of exposure
to ∆9-THC during the perinatal ages can also be harmful enough to cause certain behavioral
and neurochemical abnormalities which remain into the later stages of life. For example,
decreased locomotor activity and increased stereotypic behaviors such as self-grooming
and shaking have been observed in ∆9-THC treated rats and these were accompanied by
decreased presynaptic activity of niagro-striatal dopaminergic neurons, decreased striatal
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dopamine D1 receptor intensity, and increased dopamine turnover (Novarro et al., 1994).
Another long-term effect of ∆9-THC exposure is a change in the pattern of socio-sexual
and social interactions. This change is accompanied by an increase in the turnover of
mesolimbic dopamine (Navarro et al., 1996). Both of these studies involved adult rats who
were exposed to hashish extracts during postnatal day (PND) 1-24. These studies establish
a link between behavioral alterations in adults and the dopamine neurotransmitter system.
Dopamine is mainly produced by the action of the enzyme tyrosine hydroxylase (TH). The
CB1 receptors are present in the neurons containing TH and activation of the CB1 receptors
is associated with an increase in the level and activity of TH. Interestingly, the CB1
receptors were detected in neurons containing TH during developmental stage and
disappear from these neurons in adult brain (Hernandez et al., 2000). TH contributes to
many different aspects of brain development such as differentiation of dopaminergic
neurons, formation of connectivity, axonal guidance, and synaptogenesis (Fernandez-Ruiz
et al., 1999). Therefore, behavioral abnormalities due to perinatal ∆9-THC exposure
reported in the previously mentioned studies may be occurring because of effects of CB1
activation on TH.
The complexities of brain development are not limited to fetal and perinatal ages. The
neuronal maturation and synaptogenesis continue to occur during the adolescent ages as
evidenced by the reduction of grey matter. This reduction is mainly due to neuronal
pruning, synaptogenesis (Whitford et al., 2007) and neuronal maturation of different
neurotransmitter systems such as the endocannabinoid, GABA, dopaminergic,
serotonergic, and adrenergic systems which mature to adult levels by pruning (Sturman
and Moghaddam 2011). Exposure to ∆9-THC during adolescence is associated with certain
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neurological disorders in later life such as long lasting cognitive deficits and impaired
spatial and non-spatial learning (Cha et al., 2006). Interestingly, the learning deficits
observed by Cha et al were specific to adolescent exposure whereas adults were more
tolerant to the ∆9-THC induced learning impairments in a water maze task.
In light of the above studies concerning the CB1 receptors, it is obvious that there is a
defined pattern of CB1 expression during brain development. Any alteration in this pattern
due to exposure to exogenous substances like ∆9-THC may cause persistent changes in this
brain development due to effects on certain neuronal activities which would consequently
lead to adverse behavioral outcomes.
1.2.2

Mechanism of CB1 receptor function

CB1 receptors are the most abundant G-protein coupled receptors in the brain and are
mostly located on inhibitory neurons (GABA) and excitatory neurons (glutamate). They
are differentially distributed among the different brain regions potentially because of the
diverse functions that these receptors are involved in. Dense populations of the CB1
receptors were located in regions such as the basal ganglia, substantia niagra pars reticulata,
globus padillus (Herkenham et al. 1990). Later, using immunohistochemical analysis and
ligands specific for CB1 receptors, the sub-cellular localization of CB1 receptors in the
brain areas like hippocampus and amygdala was revealed that they are present on
presynaptic GABA interneurons (Katona et al., 2001). As demonstrated by Hewlett and
colleagues (1984), ∆9-THC-mediated CB1 activation leads to inhibition of adenylyl
cyclase activity and a decrease in cAMP production. This inhibition was not observed in
the presence of pertussis toxin which prevents the binding of Gi/o subunit to G-protein
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couple receptors. This identified the role of Gi/o subunit in the functioning of the CB1
receptor. It has been demonstrated that both cannabinoid agonist-mediated inhibition of
adenylyl cyclase and CB1-mediated adenylyl cyclase inhibition requires GTP. This
suggests a pharmacological similarity in agonist-mediated and receptor-mediated action on
adenylyl cyclase (Pacheo et al., 1991). This is further strengthened by the fact that agonistmediated inhibition of adenylyl cyclase is blocked by selective CB1 antagonists (RinaldiCarmona et al., 1994).
Functioning of the CB1 receptors is not only mediated through Gi/o signaling and
additional mechanism have been proposed involving binding of CB1 receptors to the Gs
subunit instead of the Gi/o subunit (Hewlett et al., 2004, 2005). Binding of Gs to the Gprotein receptor involves intracellular calcium signaling. One study reported that activation
of the CB1 receptors following administration of an agonist inhibits the N-type and Q-type
calcium channels. These channels normally allow the entry of calcium ions inside the
neurons, increase in the calcium current, and facilitate the release of neurotransmitters
stored in small vesicles in presynaptic neurons (Mackie and Hille 1992). It was also
reported that agonist-mediated CB1 activation can cause stimulation of inwardly rectifying
potassium channels and potassium current (Mackie et al., 1995). This study also confirmed
that CB1-mediated effects on calcium and potassium channels were dependent on GTPbinding protein, but were not consequences of cAMP depletion, because the CB1-mediated
inhibition of calcium channels was not reversed in presence of an external cAMP analogue
(Mackie et al., 1995). Later, it was proposed that the cannabinoid-mediated effects on
potassium and calcium channels occurs through binding of the G beta-gamma subunit
which dissociated from the Gi sununit following CB1 activation (Ibsen et al., 2017). This
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suggested the functioning of CB1 receptors through alternate subunits rather than only
through Gi/o subunit. Several other studies support these findings in that CB1 receptors
function by stimulating, rather than inhibiting the activity of adenylyl cyclase and increase
the production of cAMP (Maneuf and Brotchie 1997; Glass and Felder 1997; Bonhaus et
al., 1998; Felder et al., 1998). These studies observed that the CB1-mediated increase in
adenylyl cyclase activity and cAMP accumulation could be due to the recruitment of the
Gs subunit instead of the Gi/o subunit. These studies have observed that in the presence of
pertussis toxin, CB1 activation can block the inhibition of adenylyl cyclase and increase
cAMP accumulation that can be reversed by administration of CB1 antagonist (Felder et
al., 1998). This stimulatory effect of the CB1 receptors on cAMP implies the participation
of the Gs subunit. However, the high abundance of the Gi/o subunit lowers the affinity of
the Gs subunit to bind to the CB1 receptor, thus making the stimulatory action less likely
to occur (Glass and Felder, 1997). Another proposed mechanism of stimulatory action by
the CB1 receptor is the association with specific isoforms of adenylyl cyclase in target
tissues. While the activation of the CB1 can inhibit the 5/6 or 1/3/8 isoform families of
adenylyl cyclase, it can also activate the 2/4/7 isoform family of adenylyl cyclase resulting
in a stimulatory action (Rhee et al., 1998). Alternatively, the differential binding of subunits
to CB1 receptors may be due to the different agonists used in previous studies. Different
agonists can cause different conformational changes in CB1 receptors and these
conformational changes dictate the binding of specific subunits (Ibsen et al., 2017).
1.2.3

Function of CB1 receptor in mediating behavior

After the discovery that the CB1 receptor was a primary target of the cannabinoids, they
have been studied for their role in memory, as well as in other types of behaviors. Stress is
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one of the primary factors that plays a fundamental role in mental illnesses like depression
and anxiety. When exposed to the same type of stress repeatedly, it leads to habituation
which is a process of progressive decrease in the stress response after repeated exposure to
same stress (Patel and Hillard, 2008). Stress habituation is controlled by glutamate release
and has a prominent effect on memory encoding because it determines the ability to
distinguish between stimuli that are worthy of memory consolidation and stimuli that are
not. Stress habituation and memory are two interlinked processes that are controlled by the
CB1 receptor through glutamate release (Litvin et al., 2013).
Social discrimination is a behavioral paradigm used to test social memory in animals.
Social memory is predicated by the discriminative indices such as amount of time the
animal spends with a novel or a familiar conspecific. Both genetic and pharmacological
blockage of CB1 receptor in mice caused a significant increase in the discrimination indices
indicating that CB1 receptor have a role in social memory (Litvin et al., 2013). Improved
performance of CB1 knockout mice in an active avoidance task has been reported (Martin
et al., 2002). Blockage of the CB1 receptor in adult mice is associated with improvement
in working memory tasks observed in an avoidance task in the elevated T-maze suggesting
significant improvement in memory acquisition and consolidation due to the suppression
of the CB1 receptors (Takahashi et al., 2005). On the other hand, activation of CB1 by an
agonist either by systemic administration or by direct injection into the hippocampus
induced memory impairments in a water maze task and in a T-maze (Cha et al., 2006;
Abush and Akirav 2010). Activation of CB1 receptors in the medial-prefrontal cortex via
adeno-associated virus vector-mediated gene transfer induced impairment in the
recognition memory (Klugmann et al., 2011).
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The negative effects of CB1 activation on learning and memory could be due to changes
in the level of anxiety mediated by CB1 activation because anxiety facilitates learning and
memory (Litvin et al., 2013). Anxiety is a type of emotional response that involves the
release of diverse neurotransmitters from different brain regions. CB1 receptor control
anxiety because of their retrograde function that inhibits the release of neurotransmitters
(Ruehle et al., 2012). Genetic or pharmacological manipulation of the CB1 receptors is
associated with prominent effects on anxiety and the high density of expression of CB1
receptors in the brain areas, such as the amygdala that mediates emotions, strengthens the
concept of the involvement of CB1 receptors in anxiety behavior (Kathuria et al., 2002).
CB1 activation has a biphasic effect on anxiety as demonstrated by low doses of agonists
inducing an anxiolytic response whereas high doses of agonists induce an anxiogenic
response (Vivors et al., 2005). In addition, CB1 receptors in different brain regions
differentially regulate anxiety. In the medial prefrontal cortex and dorsal hippocampus
(Rubino et al., 2008; Libosa et al., 2015), CB1 activation induced by administration of
either direct or indirect agonists produced anxiolytic effects in the elevated plus maze.
Whereas, administration of direct agonist in the amygdala produced anxiogenic effects
(Rubino et al., 2008). Anxiogenic effects were also observed following systemic
administration of indirect agonists (Manduce et al., 2015). In contrast, Libosa and
colleagues (2015) reported anxiolytic effects following CB1 activation by an indirect
agonist in the amygdala. The basis for this disparity may be due to the fact that anxiety
behavior is sensitive to the state of emotionality of the animal where anxiolytic behavior is
displayed when tested under low emotional arousal but a state of high emotional arousal
masks the anxiety (Morena et al., 2016).
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Resident intruder tests and chronic unpredictable mild stress models (CMS) are two valid
animal behavioral paradigms used to measure aggression and depression, respectively. To
investigate the role of the CB1 receptors in emotional responses, CB1 knockout mice were
tested in the resident intruder test and the CMS. Anhedonia, a loss of responsiveness to a
pleasurable event, is a measure of depressive behavior exhibited by animals during CMS.
The number of attacks made by an intruder when it is placed into a resident’s cage measures
aggressive behavior. CB1 knockout mice exhibited decreased preference for sucrose water
in the CMS and increased intruder attacks in the resident intruder test (Martin et al., 2002).
The CB1 receptors are also associated with social behaviors that are an integral part of
learning and developing skills necessary for survival of a group or species. Several studies
have addressed the role of CB1 receptors on social behaviors by examining the effects of
CB1 agonists or antagonists on play behavior, the earliest form of social behavior (Trezza
et al., 2010). CB1 activation by systemic administration of either direct or indirect agonists
was found to be associated with a reduction in play as demonstrated by decreased
frequency of play solicitation and reciprocation (Trezza and Vanderschuren 2008a, 2008b).
In contrast, another study reported an increase in the overall play activity induced by CB1
activation. Pinning is one of the characteristic activities performed by a pair of rats when
they are subjected to play. This activity is an important measure of play behavior because
execution of pinning happens by equal involvement of both partners. CB1 activation by an
indirect agonist induced an increase in the number of pinning in playing rats and this
increase was masked in presence of CB1 antagonist (Trezza and Vanderschuren 2009). A
similar finding was also reported by Manduce et al. (2015) where CB1 activation by
endogenous cannabinoids increased the amount of pinning and pouncing during play
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sessions in adolescent rats. Another line of thought concerning the mechanistic basis of
social play is the hypothesis that there is a co-activation of the cannabinoid, opioid, and
dopamine receptor system during the social play. Social play has been reported to be
reduced in rats that were treated with a direct CB1 agonist. However, administration of an
indirect agonist enhanced social play and this involved co-activation of the dopamine and
opioid receptor systems along with CB1. This enhancement of play induced by the
activation of CB1 disappeared in the presence of either an opioid or a dopamine receptor
antagonist. In contrast, the presence of a CB1 antagonist can suppress the enhancing effect
of the opioid agonist morphine on social play (Review: Trezza et al., 2008).
Considering that CB1 activity is strongly influenced by ∆9-THC exposure and that there is
a significant role for CB1 receptors in brain development as well as in mediating anxiety
and social behavior, it is possible that exposure to ∆9-THC during a critical window of
brain development can have a long-term impact on these types of behaviors. This research
will address this issue by testing the following central hypothesis: Repeated exposure of
juveniles to ∆9-THC alters the CB1 signaling pathways leading to long-term effects
on behaviors related to anxiety and social interactions.
1.3
1.3.1

Review of Literature
Elevated plus maze (EPM)

The EPM is a widely accepted and validated animal model designed to measure the anxiety
level in rats and mice (Hogg 1996). The EPM apparatus consists of two closed arms and
two open arms of equal size and is elevated to a considerable height above the ground. The
open arms have a higher illumination compare to the closed arms. The anxiety level in rats
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or mice is predicated based on their natural tendency to avoid illuminated areas. Both
forced and voluntary passages into the open arm are associated with increased plasma
corticosterone levels and increased freezing which are hormonal and behavioral changes
indicative of increased anxiety, respectively (Pellow et al., 1985). The natural exploratory
behavior of rat and mice normally occurs more in the closed arms and the time spent in the
closed arms increases when the animals are exposed to anxiogenic compounds. However,
administration of anxiolytic compounds reduces the natural aversion to the open arms and
increase the exploration and time spent in the open arms (Hogg 1996). In recent studies,
the EPM has also been used to measure locomotor activity which is indexed by the
exploration within the closed arm (Brujinzeel et al., 2016) and the number of closed arm
entries (Huang et al., 2010). Table 1.1, below, indicates different types of behaviors
reflected by exploration of animal in different parts of EPM.
Table 1.1

Specific behaviors represented by level of exploration performed by rats or
mice in different arms of elevated plus maze

EMP Parameters

Associated Behavior

Reference

Fraction of time spent in

Anxiety behavior

Hogg 1996

Anxiety behavior

Hogg 1996

Locomotor activity

Brujinzeel et al., 2016

open arm exploration

Fraction of time spent in
closed arm exploration
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Table 1.1 (continued)
Fraction of number of open

Anxiety behavior

Komada et al., 2008

Locomotor activity

Huang et al., 2010

arm entries
Number of closed arm
entries

There are a fair number of studies examining the effect of ∆9-THC on anxiety by using the
elevated plus maze. One study reported that administration of ∆9-THC at a dosage of 0.75
mg/kg (i.p) 30 min before the trial in adolescent male rats can significantly induce
anxiolytic effects as demonstrated by increased open arm exploration. This study further
examined the potential involvement of serotonin receptors (5HT1A) in the ∆9-THCinduced anxiolytic effects and found attenuation of ∆9-THC-induced anxiolytic effects in
presence of a 5HT1A antagonist (Braida et al., 2007). Similar findings were also reported
by another study which observed anxiolytic behavior in adolescent rats receiving ∆9-THC
(i.p) in the dosage range of 0.075-1.5 mg/kg 30 min prior to testing in the EPM (Rubino et
al., 2007). This study suggested the mechanistic basis of CB1-mediated anxiety involves
the activity of several kinases.
cFOS is an activator protein that forms transcriptional factor by dimerization with members
of jun family and can be used as a mapping tool to resolve the neuronal circuits underlying
the behaviors induced by stress including anxiety (Kovacs 1998).

CREB is a

transcriptional factor that is activated in response to cAMP and associated with depressive
or emotional behaviors (Barrot et al., 2002). CREB-mediated gene expression is closely
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related to the activity of kinases such as protein kinase A (PKA) which phosphorylates
CREB and calcium/calmodulin protein kinase II (CaMKII) which inhibits CREB by
preventing dimerization and binding of CREB-related proteins (Rubino et al., 2007). In the
EPM, cFOS phosphorylation was increased in behavioral control rats compared to rats that
did not go through testing. ∆9-THC treatment altered this scenario in that there was a
decrease in the level of phosphorylated cFOS in the prefrontal cortex (PFC) and amygdala.
In the hippocampus, testing in the EPM did not have any effect on CREB, CaMKII, PKA,
and extracellular-signal-regulated kinase (ERK) signaling. ∆9-THC treatment also altered
this scenario by reducing the activity of CaMKII which, in turn, triggers CREB activation.
All of the ∆9-THC-induced effects observed in this study were reversed in the presence of
the CB1 antagonist AM251 which suggests CB1-mediated effects on all of these kinases
and transcription factors. In PFC, there was an inhibitory effect of EPM on CaMKII, but
there was no prominent effect of ∆9-THC (Rubino et al., 2007). This disparity of effects in
different regions could be due the fact that these three regions differentially modulate the
anxiety induced by ∆9-THC. Direct administration of ∆9-THC into the hippocampus and
PFC produced anxiolytic effects whereas, direct administration of ∆9-THC into the
amygdala led to anxiogenic effects (Rubino et al., 2008b). On the other hand, an anxiogenic
response was observed at the dosage of 2.5 mg/kg ∆9-THC (i.p) given to adolescent and
adult rats 30 min before the EPM trial with adults showing significantly more effects at the
same dosage (Schramm-Sapyta et al., 2007). An anxiogenic response was also observed in
adolescent rats who were given gradually increasing doses of ∆9-THC on the scale of 2.510 mg/kg for 11 consecutive days. This anxiogenic response persisted for seven days
following the last exposure (Stopponi et al., 2014). However, no effects were observed 30
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days following the administration using the same dosing scale and regimen (Rubino et al.,
2008a).
The most common route of exposure to ∆9-THC in humans at adolescent ages is through
inhalation in the form of smoke by ∆9-THC cigarettes or pipes. Recently, Brujinzeel and
colleagues (2016) simulated this exposure paradigm by exposing 55 days old male rats to
cannabis smoke containing 5.7% ∆9-THC. The concentration of ∆9-THC in the serum
following the exposure was found to be 225 ng/ml which is similar to the level detected in
the humans following smoking cannabis. This study observed no significant effects on
open arm activity but did observe an increase in exploration of closed arm in treated rats
as compared to control rats. This suggests that ∆9-THC-induced increase in locomotor
activity which was then confirmed by using open field test. This increased locomotion was
only observed when tested immediately after the exposure and the effects were no longer
detected at 4 hours following exposure. However, this time-line of appearance and
disappearance of effect does not always hold true because other studies reported
contradictory findings. Chronic administration of 3 mg/kg (i.p) ∆9-THC to male mice at
adolescent or adult ages for three weeks did not change the level of anxiety in any group
when the EPM test was performed immediately following treatment. When the EPM test
was performed six weeks following the cessation of exposure, there was an increased
aversion to the open arms in the treated rats (Murphy et al., 2017). Another study
investigated the effect of 10 mg/kg ∆9-THC administered subcutaneously in male mice
daily for 10 consecutive days then followed by administration of CB1 antagonist
SRA141716 (i.p) on the last day in sub-samples of both ∆9-THC and vehicle mice. Mice
that received ∆9-THC alone performed in the same way as controls in terms of percent
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open arm entries and percent time in the open arms. ∆9-THC-treated mice that were given
a challenge of 3 mg/kg of SRA141716 exhibited a sharp decrease in the percent time in the
open arms and percent open arm entries as compared to their respective controls. These
data suggest the anxiety inducing effect of ∆9-THC withdrawal (Huang et al., 2010), which
is also observed in humans (Winstock and Lea 2009). However, rats and mice may have a
different time-line of anxiogenic effects following ∆9-THC withdrawal because Rubino
and colleagues (2008a) observed no effects in rats 30 days after the last exposure but
Murphy and colleagues (2017) observed effects in mice following 42 days after the last
exposure (Murphy et al., 2017).
1.3.2

Social play

Play is a deceptive term as it not so easily defined as it sounds because of the ambiguity in
the categorizing the behavior as “playful behavior”. Play is associated with many aspects
of development and especially important is the fact that it provides a supportive
environment in which children can develop the skills to interact with others. In most
mammals, play is generally observed between the ages of weaning and sexual maturation.
This phenomenon is very important in juvenile animals and one of the determining factors
in establishing adult behavior (Anne and Einon, 1981). There are many theories concerning
the concept of play behavior but the empirical evidence to actually define the boundaries
of actions involved in play are still questionable. This may be because actions involved in
play are so random and seem to be performed without any purpose (Panksepp et al., 1984).
Because of the ambiguity in these actions and the absence of a specific purpose in
performing them, the biochemical mechanism that regulate the programming of this
behavior is not well characterized (Blake and McCoy, 2015). However, play is thought to
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be tightly regulated by some unidentified brain circuits not only in the short term but
throughout the life span of an organism (Panksepp et al., 1984).
1.3.2.1

Social play in developmental disorders

It has also been determined in human juveniles that play behavior is necessary for the
development of normal social interactions. Play behavior therapy is currently being used
as a treatment in several neurodegenerative disorders (Dawson 2008). Social play has a
prominent role in identification and diagnosis of the autism spectrum disorder. Autism is a
developmental disorder characterized by dysfunctions in specific aspects of behavior
including the ability to participate in social interactions, the ability to communicate, and
characterized by repetitive behaviors and lack of interests (Hille 2004). These deficits are
similar to alterations in social play as evidenced by the significant differences in social play
activities observed in children diagnosed with autism. In addition, a modified form of play
that would facilitate autistic children to engage in play could be an effective therapy in
autism (Restall and Magill-Evan 1993). Alterations in play behavior is also associated with
Attention Deficit Hyperactivity Disorder (ADHD). When observing patterns of play, preschool children with ADHD exhibited different patterns of play as compared to non-ADHD
children. In ADHD children, play activities were decreased while non-play activities were
increased. There was also a decrease in the sustained attention of these children and an
increase in the frequency of transition from one activity to another (Alessandri 1992).
1.3.2.2

Structure and neurobiology of play

Based on our present knowledge about most behaviors, the molecular mechanisms
controlling a specific behavior are not well characterized and there is no single gene
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directly involved in the control of certain behaviors (Peills and Peills 1993, Popova 2006,
Blake and McCoy 2015). This is especially true for play. Play is a complex form of
behavior involving a variety of random actions performed by the individuals involved that
are not only difficult to capture in words but the boundaries between the different forms of
these random actions are even difficult to define. Despite play being a very complex and
random phenomenon, it does have a distinct role in the establishment of normal social,
sexual, and aggressive behavior in adults and it is one of those essential tasks required for
the normal development of the brain (Panksepp et al., 1984).
In an experimental setup, social play in rats can be observed by documenting the
occurrence of certain parameters such as pouncing, chasing, grooming wrestling, napping,
pinning, sniffing and crawl over. A bout of play generally starts by one rat approaching or
soliciting another to play. The soliciting rat attempts to sniff or rub the neck of the play
partner and from this, chasing, boxing, wrestling crawling, and/or pinning may follow. The
time that two rats spend involved in these activities is considered as the time of play. Each
of these activities has been validated to represent specific type of behavior (Table 1.2).
From the neurobiological point of view, social play is influenced by multiple centrally
acting neurotransmitters such as acetylcholine, adenosine, catecholamine, dopamine,
serotonin, opioids, and noradrenaline (Vanderchuren et al., 1997).
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Table 1.2

Different types of activities performed during the act of play and associated
behaviors represented by each activity

Play Activities

Behavior

Reference

Sniffing/anogenital sniffing

Contact behavior

Peills and McKenna 1995.

Self-Grooming

Aggressive behavior

Mickzek 1974

Crawling over/under

Unfamiliar situation

Peills and McKenna 1995.

Chase

Appetitive play

Panksepp and Beatty
1980.

Nape attack

Play solicitation

Peills and McKenna 1995.

Pinning

Play variable

Panksepp and Beatty
1980.

Wrestling/Time of wrestling

Consummatory play

Panksepp and Beatty
1980.

1.3.2.3

Effect of ∆9-THC on play behavior

Miczek (1974) first reported the effect of ∆9-THC on aggressive interactions by observing
a dominant adult male rat and a subordinate adult male rat inside a dark chamber. When
the subordinate rats were administered 4 mg/kg (i.p) of ∆9-THC, the defensive behaviors
of the submissive rats were decreased as evidenced by the increased incidence of severe
injuries inflicted by the dominant rat during the test. When the dominant rat was
administered the same dosages of ∆9-THC, there was reduction in the frequency of
aggressive attacks towards the subordinate conspecific. In a subsequent study, injection of
5 mg/kg of ∆9-THC (i.p) into adult mice resulted in a reduction in exploratory behavior
and an increase in immobility in male-to-male encounters. In male-female encounters,
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there was a reduction in sexual behaviors as indicated by decrease in the number of mounts
and chases followed by sniffs (Cutler and Mackintosh 1984).
Active social interaction of two rats placed into the same arena can be measured by the
time it takes for the rats to approach each other or for one rat to move towards a stationary
conspecific. Higher latency indicates a reduced level of interaction. As reported by Malone
and colleagues (2009), the latency of initial interaction was reduced in adolescent rats
treated with 1 mg/kg of ∆9-THC (ip) but this reduction was not observed at higher dosages
(3 or 10 mg/kg). Similarly, an increase in investigative behavior was observed in adult rats
(PND90) receiving 2 mg/kg of ∆9-THC (sc) during PND2-10 (Newsome and Kelley,
2008). However, during exposure, no effect on total social interactions were observed in
adult and adolescent rats receiving a chronic dosages of 5 mg/kg ∆9-THC (ip). However,
when a social interaction test was performed 16 days following the last administration of
∆9-THC, there was a decline in social interactions in the treated rats (Quinn et al., 2008).
A decline in social interactions as evidenced by reduced body sniffing and allo-grooming
and increased rearing was observed in adult rats receiving 2 mg/kg of ∆9-THC as compared
to saline-control rats. Interestingly, this study also reported no differences in social
interactions between ∆9-THC-treated rats and ethanol-control rats (Slamberova et al.,
2016) suggesting that it is possible that ethanol, which is the most frequently used solvent
in ∆9-THC studies, may have some effect on behavioral performance in rats.
1.4

Proteomic Approach to Study Behavior

Proteomics involves the study of complete protein complement of the genome of an
organism. Recently, this technology has been employed to study the protein profiles in
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rodent brain to study behavioral and/or developmental changes (Richard et al., 2002). The
gel-based proteomics is one of the classic methods used for protein identification and
quantification. This method involves the separation of proteins by using two dimensional
polyacrylamide gel electrophoresis (2D PAGE) and identification of proteins by using
Mass Spectrometry (MS) or Tandem Mass Spectrometry (MS/MS; Chevalier 2010). Gelbased proteomics has been employed to study the changes in the protein expression in mice
with anxiety like behavior and psychomotor deficits. The differentially expressed proteins
were

then

analyzed

in

Ingenuity

Pathway

Analysis

(IPA;

Qiagen

Inc.,

https://www.qiagenbioinformatics.com) to predict the biofunctional categories in which these

differentially expressed proteins were involved in (Abdullah et al., 2011). Similarly, the
gel-based proteomic technique was used to evaluate the differentially expressed proteins
in developing brains of rats and mice (Quinn et al., 2008; Taoka et al., 2000; Fountoulakis
et al., 1999) or to quantify the differentially expressed proteins in different brain regions
obtained from human Alzheimer’s Disease patients (Schonberger et al., 2001). The gelbased proteomics method can also be modified to specifically identify oxidatively modified
proteins or phosphorylated proteins in tissues to obtain more specific information about
experimental or disease conditions (Butterfield et al., 2006). Another method utilized in
proteomics is the label free proteomic approach, which involves digestion of individual
protein samples followed by separation of digested peptides by using liquid
chromatography. The separated peptides are then introduced into a mass spectrometer to
generate the MS/MS spectra for each identified peptide (Zhu et al., 2010). The number of
spectra matched to specific peptide in a protein is a linear measure for relative abundance
of the protein (Zhang et al., 2006). In this study, we employed the label free shotgun
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proteomic approach to study the expression pattern of proteins in the amygdala of
adolescent rats exposed to ∆9-THC as juveniles.
Considering the increased availability of marijuana edibles and the adverse effects of its
active component (∆9-THC) on brain development, this research was designed to
investigate the long-lasting effects of ∆9-THC ingestion at early stage of life in rat model.
Chapter II will investigate the ∆9-THC-mediated effects on anxiety level and performance
during social interaction test at adolescent stage. Chapter III will not study behavior but
will address proteins and canonical pathways affected following repeated ∆9-THC
ingestion. Chapter IV will analyze the canonical pathways involved in the social behaviors,
and alterations in these canonical pathways following repeated ∆9-THC ingestion. Chapter
V will be the overall conclusion emphasizing the adverse behavioral outcomes, and
alterations in canonical pathways at adolescent ages due to unwanted activation of CB1
receptors at juvenile ages.
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EFFECT OF REPEATED JUVENILE EXPOSURE TO
D9-TETRAHYDROCANNABINOL ON ANXIEYT-RELATED BEHAVIORS AND
SOCIAL INTERACTIONS IN ADOLESCENT RATS

2.1

Introduction

Cannabinoids are a group of terpenophenols present in the granular trichomes of the plant
Cannabis sativa. Because of the psychoactive properties, cannabis preparations, such as
marijuana and hashish, have been used recreationally for centuries and remain one of the
most widely used illicit drugs (Brujzeel et al., 2016; Substance Abuse and Mental Health
Services Administration, 2014; Fellermeier et al., 2001). After the discovery of the
potential medical application of marijuana, there has been much debate about its
legalization for medical use. The debate was initiated in 1972 when the National
Organization for the Reform of the Marijuana Laws (NORML) filed a petition with the
Bureau of Narcotics and Dangerous Drugs to reschedule marijuana under the Controlled
Substances Act. However, crude marijuana remains classified with the Schedule I drugs,
which are described as ‘drugs with no accepted medical applications in treatment in
United States’ (Zeese, 1999). Despite the strict regulation of marijuana, its use has
increased dramatically in the past few decades. This widespread use is a growing concern
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especially because of the abuse of the drug by pregnant women and by adolescents. In
fact, there are many behavioral and neurological disorders in human and animal studies
associated with marijuana exposure either during the prenatal period (Higuera-Mates et
al., 2015) or during adolescent ages (Fontes et al., 2011; Fried et al., 2002; Meier et al.,
2012; Pope et al., 2001). However, exposure to marijuana is also increasing in a very
unlikely population. From 2006 through 2013, the rate of marijuana exposure among
children 5 years old or less rose 147.5% in the United States. In states that have legalized
marijuana, the exposure rate increased almost 610% during the same period (Onders et
al., 2016). An even earlier study reported that marijuana exposure among children 9 years
old or less increased by 30.3% per year between 2005 and 2011 in decriminalized states
but did not change in nonlegal states (Wang et al., 2013). In both studies, these data were
obtained from reports to Poison Control Centers and it is therefore likely that many
additional exposures are occurring that go unreported. While literature has expanded in
recent years with respect to the behavioral and neuroanatomical effects of adolescent and
prenatal exposure to marijuana in laboratory animals, very little information is available
on the persistent effects of marijuana exposure during developmental periods that mimic
exposure in young children.
The main psychoactive component of marijuana is Δ9-tetrahydrocannabinol (Δ9-THC)
(Gaoni & Mechoulam 1964) which activates the cannabinoid receptors, including type I
cannabinoid receptor (CB1). CB1 receptors are abundant in the brain (Devane et al.,
1988), appear during fetal development (Berrendoro et al., 1998), and the highest density
of CB1 receptors occur in brain regions which are directly involved in brain
developmental processes (Fernandez-Ruiz et al., 2000). During development, the CB1
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receptor is involved in synaptogenesis, the formation of connections across the neurons
which is essential for efficient processing of adult cognition (Basavarajappa et al., 2009).
Synaptogenesis peaks during the postnatal period suggesting that any inappropriate
activation of the CB1 receptor during this postnatal period, such as that which occurs
during Δ9-THC exposure, could result in altered synaptic connections. This could lead to
neurobehavioral abnormalities that may not be observed until later stages of life. In fact,
many behavioral abnormalities have resulted from developmental Δ9-THC exposure in
animal studies. Most of these studies have focused on the behavioral abnormalities
observed following Δ9-THC exposure either during pregnancy (Hutchings et al., 1991;
Newsome & Kelly 2008; Rubio et al., 1995, 1998) or adolescence (Fleming et al., 2016;
Keeley et al., 2015; Zamberletti et al., 2012; Realini et al., 2011; Rubino et al., 2011;
Quinn et al., 2008; Rubino et al., 2008; Cha et al., 2006; Jarbe et al., 1998; Miczek &
Barry 1974; Ueki et al., 1972).
Since the unintentional exposure of marijuana in children is increasing dramatically
(Onders et al., 2016; Wang et al., 2013), it is imperative that research focus on
investigating whether or not this pediatric exposure scenario can lead to persistent
abnormalities. The majority of pediatric exposures result from the ingestion of Δ9-THCinfused edibles which are indistinguishable from their equivalent non-infused food
product with respect to look, smell, and taste (Wang et al., 2017). For commercial
products, several states with legalized marijuana (Alaska, Oregon, Colorado, and
Washington, California) have limited the amount of Δ9-THC that can be in a single
serving (5-10 mg; Gourdet et al., 2017). However, multiple servings of Δ9-THC are
allowed in a single edible (i.e., brownie, cookie, chocolate) and children could easily
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consume multiple servings and even multiple edibles (Gosh et al., 2015). Even with
limitations placed on the number of servings, the total Δ9-THC concentration in one
edible can reach as high as 100 mg. Some individual edibles contain up to 1000 mg
(Richards et al., 2017). In addition, the exposure levels from homemade Δ9-THC-infused
edibles, which are not restrained by regulations, could be even higher. Thus, the range of
exposure levels in children can be very wide. For this investigatory project, we selected
10 mg/kg/day which has been utilized in previous studies exposing developing rodents
(Burston et al., 2010; Moore et al., 2010; Philippot et al., 2016). The human equivalent
dose for this dosage in a 5 year old child (17-20 kg) calculates to be 40-48 mg/day.
However, it is not clear if this dosage recapitulates exposure levels in children.
This research project was designed to determine if exposure to the psychoactive
component of marijuana Δ9-tetrahydrocannabinol during the postnatal period altered
anxiety and social behaviors in adolescent rats. Since rat brain development at postnatal
day (PND) 7 has historically been used as a rough estimate of human brain development
at birth (Clancy et al., 2007), the exposure treatment period utilized in this project was
from PND10-16 which should be equivalent to early childhood ages in humans (Beck et
al., 2011).
2.2
2.2.1

Materials and Methods
Chemicals
Δ9-tetrahydrocannabinol was provided by the National Institute on Drug Abuse.

All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).

46

2.2.2

Animals

A breeding colony of adult male and female Sprague Dawley rats (CD IGS; Harlan
Laboratories, Indianapolis, IN) were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited facility with temperature control (22
± 2̊ C) and with lights on between 0700 and 1900 for a 12-h dark-light cycle. Tap water
and LabDiet rodent chow were freely available during the experimentation. The
procedures used in this project were approved by the Mississippi State University
Institutional Animal Care and Use Committee. From this colony, male and female rat
pups were obtained and the day of birth was considered as PND0. On PND10, rat pups
within the same litter were assigned to different treatment groups. There were always a
representative control animal of the same sex present in each litter to match the Δ9-THCtreated animal to ensure equal distribution of animals to different treatment groups.
2.2.3

Exposure

Beginning on PND10, rats were exposed daily for 7 days to either corn oil (vehicle) or 10
mg/kg Δ9-THC by oral gavage at a volume of 0.5 ml/kg. Solutions were delivered to the
back of the throat using a 50-ul tuberculin syringe equipped with a 1-inch 24-gauge
straight intubation needle (Popper and Sons, Inc., New Hyde Park, NY). At weaning, the
rats were weaned and remained housed with littermates throughout behavioral testing.
2.2.4

Elevated plus maze (EPM)

The elevated plus maze was constructed of black-painted wood and consisted of four
arms (50 X 10 cm), two open and two enclosed (40 cm wall), intersecting at
perpendicular distances to each other to form a 90° angle and elevated to a height of 50
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cm above the floor. On PND29, the rats were transported to the testing room, placed in
the center of the maze and allowed to explore the maze for 5 min. After each test, the
maze was cleaned with 70% ethanol and dried. Each test session was recorded using a
remotely operated Canon EOS Rebel digital camera. The videos were scored by two
observers who were blind to treatment.
The observers scored the following behavioral parameters: (1) number of entries into the
open arms, (2) number of entries into the closed arms, (3) time spent in the open arms, (4)
time spent in the closed arms, and (5) time spent in the central square. From these data,
the (6) percent open arm entries and (7) percent open arm time were calculated. In
addition, the following ethological oriented parameters were scored: (8) number of
stretch-attend postures (defined as exploration of the open arm with the front part of the
body, while the hind region remains in the closed arm) and (9) number of head-dips
(protruding the head over the ledge of an open arm and downwards towards the floor
regardless of the location of the animals body). Entries into closed arm or open arm were
counted only when all four paws including tail of rats were in respective arms.
Different anxiety levels have been observed under different levels of illumination
following stimulation of the endocannabinoid system in rats (Haller et al., 2002). Thus,
testing was conducted under two different illumination scenarios. The first was high
illumination in which the illumination was ~600 LUX in the open arms and ~100 LUX in
the closed arms. For this scenario, the controls (n=11 of each sex) were derived from 8
litters and the Δ9-THC treated (n=12 of each sex) were derived from 10 litters. The
second was low illumination in which the illumination was ~10 LUX in the open arms
and ~2 LUX in the closed arms. For this scenario, the controls (n=26-30 of each sex)
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were derived from 22-23 litters and the Δ9-THC treated (n=20 of each sex) were derived
from 15-16 litters. There were never more than two animals of the same treatment and
sex from same litter used in any aspect of this study.
2.2.5

Social behavior (PND37-38)

Since previous behavioral test can affect the performance in subsequent behavioral test
(Blokland et al., 2012; Mellwain et al., 2001), social behavior was conducted only on rats
tested under low illumination in the elevated plus maze. The low illumination was
selected over high illumination because, intuitively, it was considered to be less invasive
and exerts less stressful effect. The social play test requires two rats of the same treatment
in order to obtain a single replication and this is the reason for there being a greater
numbers of litters and rats tested under low illumination in the elevated plus maze as
compared to those tested under high illumination. The behavioral arena was a clear empty
litter-cage with bright light (600 lux). Following a 24 hour isolation period, two rats of
the same treatment, sex, age and size but from different litters were placed into different
corners of the cage and allowed to interact for 10 min. Each test session was recorded
using a remotely operated Canon EOS Rebel digital camera. After each test, the cage was
emptied, cleaned with 70% ethanol, dried, and refilled with fresh litter. The videos were
scored by two observers who were blind to treatment.
The observers scored the behavioral parameters as previously described (Ku et al., 2016;
Himmler et al., 2013; Trezza et al., 2010; Varlinskaya & Spear 2002; Vanderschuren et
al., 1997). These included: (1) time to first interaction, (2) frequency of self-grooming,
(3) frequency of social exploration (body or anogenital sniffing or licking), (4) frequency
of crawling over and under, (5) frequency of chasing, (6) frequency of pouncing/nape
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attacks (playful attacks directed at the nape of the neck), (7) frequency of play fighting
(boxing and wrestling), (8) frequency of pinning (one animal lying with its back on the
floor with the other animal standing over it), and (9) the time spent play fighting. When
scoring these parameters, the behavior of each individual rat was not recorded and the
score obtained is a combined measure of the occurrence of the behavior in both rats
regardless of which rat performed/initiated the behavior.
2.2.6

Statistical analysis

All data were subjected to testing by analysis of variance (ANOVA) using the SAS
statistical package (SAS Institute Inc., Cary, NC). For body weights, the data were tested
using the general linear model with a repeated measures paradigm and was found to
violate the assumption of sphericity. Therefore, subsequent analysis using the Mixed
procedure (Littell et al., 1996) was conducted with a repeat measures paradigm with a
Huynh-Feldt covariance structure (Huyuh & Feldt 1970), followed by separation of
means using least squares mean (LSM). The analysis identified significant differences in
the main effects (sex, treatment, and day) and all possible interactions.
Behavioral data were analyzed by ANOVA using the Mixed procedure followed by mean
separation by Least Square Means (LSM). Prior to analysis, the distribution of the
conditional residuals for the behavioral data were evaluated for each parameter to
determine the appropriateness of the statistical model. Any parameter not found to be
sufficiently normally distributed were subjected to Blom’s transformation in SAS using
the PROC RANK procedure with the NORMAL option (Altman 1991). The analysis
identified significant differences in the main variables (sex, treatment and day) and all
possible interactions. If either main effect was significant or tending towards
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significance, an additional lower level analysis (one-way ANOVA) was performed to
determine differences between sexes within each treatment or treatment within each sex.
The criterion for significance was set at p < 0.05.
2.3
2.3.1

Results
Weight gain

Oral exposure to 10 mg/kg Δ9-THC significantly reduced the amount of weight gained in
both females and male pups (Figure 1) with no statistically significant difference between
sexes. No signs of toxicity were observed in the pups. The pups were not lethargic and
did not exhibit any abnormal movements or behavioral patterns during the exposure
period. By the time of behavioral testing, there were no longer any statistically significant
differences between treatment in either sex. However, male rats weighed significantly
more than female rats (P=0.0001).
2.3.2

Elevated plus maze

For the elevated plus maze, the parameters measured under high illumination and the
parameters measured under low illumination were analyzed separately. For both high and
low illumination, the overall statistical analyses indicated that there was no significant
overall effect of treatment and no significant treatment × sex interaction on any activity
parameter associated with any open arm activity but some significant differences were
detected in certain parameters. When detected, an additional lower level analysis was
conducted to determine the presence of either sex differences within each treatment or
treatment differences with each sex.
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2.3.3

Open arm activity

There was no significant effect of treatment and no significant treatment × sex interaction
in any parameter associated with open arm activity tested under either high or low
illumination. However, statistically significant sex differences were detected in certain
parameters.
There was a significant overall effect of sex in the number of entries into the open arm
under both high illumination (F(1,32) = 7.8, p = 0.089) and low illumination (F(1,46) =
7.57, p = 0.0085). Under high illumination, males made significantly more open arm
entries than females (Figure 2A). The effects appear to be more significant between
males and females in the Δ9-THC treated group (post hoc analysis, p = 0.0145) with no
significant difference between sexes in the control group. Under low illumination, the
pattern was reversed with females making significantly more open arm entries than males
(Figure 2B) but post hoc analysis did not reveal any treatment related effects. When
calculated in terms of % of open arm entries, there was a significant effect of sex only
under high illumination (F(1,32) = 14.56, p = 0.0006). Under high illumination, both Δ9THC treated males (post hoc analysis, p = 0.0175) and control males (post hoc analysis, p
= 0.0273) had a higher % of open arm entries (Figure 2C) than their respective female
treatment group. Under low illumination, females had a slightly higher % of open arm
entries than males but there was only a trend towards significance (F(1,46) = 3.53, p =
0.0668) (Figure 2D).
There was a significant effect of sex in the time spent in the open arms under both high
(F(1,32) = 5.52, p = 0.0253) and low illumination (F(1,46) = 4.97, p = 0.0308). Under high
illumination, males spent significantly more time in the open arms than females (Figure
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1E). The effects appear to be more significant between males and females in the Δ9-THC
treated group (post hoc analysis, p = 0.0386) with no significant difference between sexes
in the control group. Under low illumination, the pattern was reversed with females
making significantly more open arm entries than males (Figure 2F) but lower level
analysis did not reveal any treatment related effects. When calculated in terms of % of
time spent in the open arms, there was a significant effect of sex under both high (F(1,32)
= 5.52, p = 0.0253) and low illumination (F(1,46) = 4.97, p = 0.0308). Under high
illumination, males had a higher % of time spent in the open arm than females (Figure
2G). The effects appear to be more significant between males and females in the Δ9-THC
treated group (post hoc analysis, p = 0.0386) with no significant difference between sexes
in the control group. Under low illumination, females had a higher % of time spent in the
open arm than males but lower level analysis did not reveal any treatment related effects
(Figure 2H).
2.3.4

Ethological oriented parameters and overall activity

Under both high and low illumination, there was no significant effect of treatment and no
significant treatment × sex interaction in any ethological oriented parameter. However,
sex differences were detected in certain parameters.
With respect to the numbers of stretch attended postures made under high illumination,
the Δ9-THC treated rats of both sexes made more as compared to their respective
controls but was not statistically significant (Figure 3A). Under low illumination, there
was a significant overall effect of sex (F(1,46) = 4.63, p = 0.0367) with males making
more than females. However, this effect appears to be more significant in the Δ9-THC
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treated groups (post hoc analysis, p = 0.0291) with no significant difference between
males and females in the control group (Figure 3B).
With respect to the number of head dips made under high illumination, there was a trend
toward significance in the overall effect of sex (F(1,46) = 3.77, p = 0.0593) with males
making more than females. Although not statistically significant, the Δ9-THC treated
males made more head dips than did the Δ9-THC treated females with similar levels
made between male and female controls (Figure 3C). Under low illumination, there was a
trend towards significance for the effect of treatment (p=0.0590). This effect appeared to
be more significant in males with greater number of head dips in the Δ9-THC treated
group than controls (post hoc analysis, p = 0.0227) with no significant difference
observed between treatment groups in females (Figure 3D).
During elevated plus maze testing, entries into the closed arms can be considered an
indicator of activity levels (Cruz et al., 1994). Overall analysis indicated that under both
high and low illumination, there was no significant effect of sex and no significant
treatment × sex interaction. However, there was a trend towards a significant effect of
treatment under high illumination (F(1,32) = 3.35, p = 0.0771) and a significant effect of
treatment under low illumination (F(1,46) = 6.02, p = 0.0180). However, the effect
appeared to mainly occur in males where Δ9-THC treated males made more entries into
the closed arms than did control males under both high (Figure 3E) and low (Figure 3F)
illumination (post hoc analysis, p=0.0453 and p=0.0210, respectively). The number of
entries was similar between the two treatment groups in females regardless of
illumination level.

54

2.3.5

Social behavior

There were no significant overall effects of treatment or sex and no significant sex ×
treatment interactions in the time to first interaction, the frequency of self-grooming, the
frequency of crawling over and under, the frequency of chasing, the frequency of
pouncing, or the frequency of pinning (data not shown). However, treatment effects were
observed on the frequency of social exploration (body or anogenital sniffing or licking),
the frequency of nape attacks, the frequency of play fighting (boxing and wrestling), and
the time spent play fighting. In these four parameters, there was no significant overall
effect of sex and no significant sex × treatment interaction.
With respect to social exploration, there was a significant overall effect of treatment
(F(1,30) = 7.65, p = 0.008). Episodes of social exploration were significantly decreased
in rats exposed to Δ9-THC as compared to that in control rats (Figure 4A). It appeared
that the reduction in social exploration occurred equally in both males and females
exposed to Δ9-THC (Figure 4A inset). With respect to the frequency of nape attacks,
there was a significant overall effect of treatment (F(1,30) = 16.93, p = 0.0004). Rats
exposed to Δ9-THC made significantly higher number of nape attacks than did control
rats (Figure 4B). Although both Δ9-THC-treated females and males exhibited increased
episodes of nape attacks, there appeared to be a greater numbers in males (Figure 4B
inset). With respect to the frequency of play fighting, there was a significant overall
effect of treatment (F(1,30) = 6.35, p = 0.0188). Rats exposed to Δ9-THC engaged in
more episodes of play fighting than did the control rats (Figure 4C). This increased level
of play fighting was present in both Δ9-THC exposed males and females (Figure 4C
inset). With respect to the time spent playing, there was an overall significant difference
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of treatment (F(1,30) =6.57, p=0.0171). Rats exposed to Δ9-THC spent a significantly
greater amount of time engaged in play fighting that did control rats (Figure 4D). This
increased amount of time spent play fighting was observed in both Δ9-THC exposed
males and females (Figure 4D inset).

Figure 2.1

Plot of weight gain of male and female rat pups exposed daily to either
corn oil (control) or 10 mg/kg of Δ9-THC as juveniles from postnatal days
10-16. Values are expressed as weight ± SE (n = 31-37). For both sexes,
weight gain in treated rats was significantly different from that in the
controls (p≤ 0.05) at all time points.
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Figure 2.2

Open arm activity in the elevated plus maze under different levels of
illumination as described in the Materials and Methods. Number of entries
into open arms under high (A) and low (B) illumination, percent entries
into open arms under high (C) and low (D) illumination, time spent in the
open arms under high (E) and low (F) illumination, and percent time spent
in the open arms under high (G) and low (H) illumination, in male and
female adolescent rats (PND29) exposed to either corn oil or 10 mg/kg of
Δ9-THC as juveniles from postnatal days 10-16. Values are expressed as
means ± SEM or percent ± SEM (n=11-30). Brackets with asterisks (*) are
statistically significant (p≤0.05) from one another
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Figure 2.3

Open arm activity in the elevated plus maze under different levels of
illumination as described in the Materials and Methods. Number of entries
into open arms under high (A) and low (B) illumination, percent entries
into open arms under high (C) and low (D) illumination, time spent in the
open arms under high (E) and low (F) illumination, and percent time spent
in the open arms under high (G) and low (H) illumination, in male and
female adolescent rats (PND29) exposed to either corn oil or 10 mg/kg of
Δ9-THC as juveniles from postnatal days 10-16. Values are expressed as
means ± SEM or percent ± SEM (n=11-30). Brackets with asterisks (*) are
statistically significant (p≤0.05) from one another
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Figure 2.4

Social behavior interactions as described in the Materials and Methods.
Frequency of social exploration (A), frequency of nape attacks (B),
frequency of play fighting (C), and time spent play fighting (D) in
adolescent rats (PND38) exposed to either corn oil or 10 mg/kg of Δ9THC as juveniles from postnatal days 10-16. Insets are values separated
by sex. Values are expressed as means ± SEM (n=10-12). Bars with
asterisks (*) are statistically significant (p≤0.05) from controls.
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2.4

Discussion

The results of this study suggest that Δ9-THC administered during the postnatal period
altered anxiety and social behaviors in adolescent rats. The first interesting observation
was that Δ9-THC decreased the expected weight gain in postnatal rats. Importantly, the
decreased weight gain was not accompanied by any signs of toxicity. Previous studies
have also observed decreased weight gain in rat pups exposed postnatally to Δ9-THC
(O’Shea et al., 2004). It has been demonstrated that short term exposure of Δ9-THC to
naïve humans and animals induces increased sleep (Babson et al., 2017; Angarita et al.,
2016). It is possible that the short term exposure to Δ9-THC induced increased sleep
resulting in decreased feeding behavior. Another hypothesis may the dose and route of
exposure used in present study may have significantly contributed to reduced weight. The
fact that Δ9-THC being an appetite stimulant as reported by other studies holds true only
at lower doses. Higher doses on the other hand are responsible for decrease in the food
intake and body weight (Cota et al., 2003).
The elevated plus maze (EPM) is a commonly used model to measure the level of anxiety
in rats and mice and the illumination of the maze plays an important factor. Combined
increases in the percentage of open arm entries and percentage of time spent in the open
arms entries are indications of anxiolytic behavior (Bradley et al., 2007; Pellow et al.,
1985), and increased ethological risk assessment behaviors, such as head dipping and
stretch attended postures, have been proposed to be sensitive measures related to anxiety
in the elevated plus maze (Cruz et al., 1994; Rodgers et al., 1999). However, we did not
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observe effects on any parameter that would suggest increased or decreased anxiety
levels in adolescent rats exposed to Δ9-THC as juveniles. While not directly comparable,
O'Shea et al. (2006) reported no effect on anxiety in pubertal rats following early
postnatal exposure to the cannabinoid receptor agonist CP 55,940. In other types of
developmental exposures, increased anxiety has been reported in adults exposed either
during the gestational/lactational period or the pubertal period to Δ9-THC (Keeley et al.,
2015; Campolongo et al., 2008) while decreased anxiety has been reported in adults
exposed as adolescents (Rubino et al., 2008; Wakeford et al., 2016). Thus, a direct link
between developmental activation of the endocannabinoid system and long term effects
on anxiety levels is not straightforward.
In the EPM, multiple studies have reported that increasing the level of illumination
decreases activity in the open arms (Garcia et al., 2005; Pereira et al., 2005). Although
not directly compared, the pattern of our data are in agreement with this line of thought in
that regardless of treatment, the rats tested under low illumination had higher numbers of
entries into the open arms and spent more time in the open arms than did the rats tested
under high illumination. It has also been suggested that anxiogenic effects of drug
exposures are more likely to be detected under low-intensity lighting, whereas anxiolytic
effects of drug exposures are more likely to be detected under higher intensity lighting
(200-400 Lux or more; Leo & Pamplona 2014). Exposure of juvenile rats to Δ9-THC
appears to induce sex specific effects in adolescents. The sex specific differences in open
arm activity were observed under high illumination, but totally disappeared when the
testing was performed under low illumination suggesting that the effects of treatment
only emerge during aversive conditions. Under these conditions, control males did
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exhibit a slightly higher open arm activity than did control females but not enough to be
statistically significant. Treatment with Δ9-THC did not alter female behavior but
exacerbated the open arm activity in males such that sex differences were detected
between Δ9-THC males and females. The basis for these sex differences could be due to
the differential effect of Δ9-THC exposure on CB1 receptor function between in males
and females. Differences exist in CB1 receptor density between males and females in the
early postnatal period (Rodriguez de Fonseca et al., 1993). Adolescent exposure to Δ9THC has been reported to induce sex-differences in the intensity of CB1 receptor-G
protein interactions and increased altered CREB phosphorylation (Rubino et al., 2008). It
is possible that Δ9-THC exposure during the postnatal period could induce sex
differences in CB1 signaling levels as well.
An increase in the number of closed arm entries is an index of locomotor activity (Hogg
1996) and regulating locomotor activity is one of the physiological functions of CB1
receptors in adolescents (Fride 2002). Increased closed arm entries were observed in Δ9THC treated males, but not Δ9-THC treated females, regardless of the level of
illumination. We also observed increased head dipping under both high (increased but not
statistically significant) and low illumination. While increased head dipping has been
associated with anxiety levels, the increase observed in this study is more than likely
merely an artifact of the overall level of increased activity. Increased spontaneous
behavior and decreased habituation has also been reported in adult mice exposed to 10
mg/kg Δ9-THC as neonates (Philoppot et al., 2016). However, other studies have
reported no effects on activity in adults exposed to Δ9-THC either prenatally or as
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adolescents (Newsome & Kelly 2008; Rubino et al., 2008) indicating that, the exposure
period and age of testing plays a role in the long term behavioral effects.
Social play is the earliest form of non-mother directed behavioral contact and is crucially
important for the normal development of social and cognitive function (Vanderschuren et
al., 1997). This behavior is observed to the greatest extent in adolescent rats as compared
to juveniles and adults and represents the characteristic social interaction between
adolescent rats (Trezza & Vanderschuren 2008). While the actual neural mechanisms
involved in social play remain to be elucidated, it has been demonstrated that social play
is strongly influenced by the endocannabinoid system in the brain and can be modulated
by drugs that directly or indirectly affect activation of the CB1 receptors (Trezza et al.,
2012; Trezza & Vanderschuren 2008). In fact, developmental exposure to CB1 receptor
agonists can have long term effects on social behavior but the results vary based on the
age of treatment, the duration of treatment, and the age of testing. For example,
gestational/lactational Δ9-THC exposure did not alter social exploration but decreased
social play in adolescents (Trezza et al., 2008) while gestational Δ9-THC exposure
increased total social interactions (all social parameters combined) in adults (Newsome &
Kelly 2008). Adolescent exposure to Δ9-THC has been reported to either decrease total
social investigation (Realini et al., 2011; Zamberletti et al., 2012) or have no effect
(Quinn et al., 2008) in adults. In the present study, juvenile exposure to Δ9-THC resulted
in a lower level of social investigation in adolescent rats but an increase in social play. At
face value, it seems unlikely that rats that exhibit lower levels of investigative
interactions would actually have increased levels of playful interactions. One possible
explanation could be that since the Δ9-THC treated rats exhibited a higher propensity for
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pouncing/nape attack which led to a higher propensity for rough and tumble play, the
level of social contact required prior to initiation of play behavior was reduced as
compared to controls. However, many consider social exploration behavior to be not
related to social play behavior and have suggested that these two parameters differ with
respect to both their ontogeny and their regulation by neurological systems (Trezza et al.,
2010; Vanderschuren et al., 1997; Spears 1999). The decreased social exploration could
be the result of the fact that the Δ9-THC treated rats spent more time engaged in play
fighting which reduced the opportunities for social exploration to occur.
Since social play can become very rough and tumble, it could be construed as a sign of
adult-like aggressive behavior especially during the late stages of adolescence. However,
it has been suggested that the rough and tumble play in developing rats is controlled by a
separate neural system than the aggressive interactions observed in adult rats (Panksepp
& Burgdorf 2003; Peills & Peills 2007). While there are conflicting reports about the Δ9THC exposure leads to aggression, it does have a profound effect on the brain reward
circuit (Katsidoni et al., 2013; Lupica et al., 2004). Social play induces a rewarding effect
and is modulated by the dopaminergic, noradrenergic, opioid, and endocannabinoid
systems, all of which have been implicated in reward (Achterberg et al., 2016; Manduca
et al., 2015; Trezza et al., 2010; Trezza & Vanderschuren 2008; Vanderschuren et al.,
2016). Thus, the modulation in social play observed in this study may involve
discoordination between these different signaling systems., The disruption of the function
of a single system during development could affect the appropriate functioning of the
other systems at the time of behavioral testing. Regardless of the system responsible for
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the altered behavior, this observed dysfunction is the result of the action of Δ9-THC on
its primary target, the CB1 receptors, during the exposure period.
The CB1 receptors are responsible for maintaining the excitatory inhibitory balance in the
brain by controlling the release of glutamate and γ-aminobutyric acid (GABA) at their
respective synapses (Castillo et al., 2012; Kano et al., 2009). This balance is crucial for
regulating and maintaining proper synaptic activity at most of the neurotransmitter
systems involved in mediating social behavior. Of interest, van Kerkhof et al. (2013)
reported both the activation of the GABAergic signaling in the nucleus accumbens core
or the inhibition of the glutamatergic signaling in the dorsomedial striatum increased
social play duration similar to that observed in this study. Therefore, a possible
hypothesis is that exposure to Δ9-THC altered the appropriate developmental events
necessary for maintaining the excitation-inhibition balance between glutamatergic and
GABAergic signaling in specific regions important in social behavior. Development of
the GABAergic inhibitory synapses occurs postnatally prior to adolescence in rodents
(De Felipe et al., 1997) suggesting that this development might be a target.
In conclusion, given the packaging used in many cannabis edibles (MacCoun et al.,
2015), it is not surprising that children find them very enticing. However, the dosages
found in these products are highly variable and unregulated but the psychotropic effects
are significantly more persistent than other routes of intake (Grotenhermen 2003)
suggesting prolonged activation of the neurological target. This is of significant concern
with respect to developmental exposures. This research provides an initial investigation
into childhood oral exposure to Δ9-THC, an exposure scenario that has recently
dramatically increased in occurrence. The results presented here suggest that repeated
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oral exposure to Δ9-THC during postnatal development has no effect on anxiety, but can
potentially affect the locomotor activity, and social behaviors during adolescence.
However, it is not clear if these are accompanied by increased levels of other behaviors
(i.e., risk-taking and novelty-seeking) that are characteristic of adolescent ages (Spears
1999). It is also not clear if exposure to lower dosages will also exert similar effects. This
study was limited to a single dosage due to the amount of Δ9-THC available for study.
Additional studies are required to investigate these issues as well as determine the
mechanisms responsible for the altered behavior observed in the present study.

66

2.5

Reference:

Achterberg, E.J.M., van Kerkhof, L.W.M., Servadio, M., van Swieten, M.M.H.,
Houwing, D.J., Aalderink, M., Driel, N. V, Trezza, V., Vanderschuren, L.J.M.J.,
2016. Contrasting roles of dopamine and noradrenaline in the motivational
properties of social play behavior in rats. Neuropsychopharmacology 41, 858–868.
Altman, D.G., 2006. Practical Statistics for Medical Research. Chapman & Hall/CRC.
Angarita, G.A., Emadi, N., Hodges, S., Morgan, P.T., 2016. Sleep abnormalities
associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review.
Addict. Sci. Clin. Pract. 11, 9.
Babson, K.A., Sottile, J., Morabito, D., 2017. Cannabis, cannabinoids, and sleep: A
review of the literature. Current Psychiatry Reports, 19, 23.
Basavarajappa, B.S., Nixon, R.A., Arancio, O., 2009. Endocannabinoid system: emerging
role from neurodevelopment to neurodegeneration. Mini Rev. Med. Chem. 9, 448–
462.
Beck, M.J., Padgett, E.L., Parker, G.A., Maginnis, G.M., Toot, J.D., Varsho, B.J.,
Varsho, J.S., 2011. Nonclinical juvenile toxicity testing, in: Hood, R.D. (Ed.),
Developmental and Reproductive Toxicology. CRC Press, Boca Raton, FL, pp.
302–345.
Belue, R.C., Howlett, A.C., Westlake, T.M., Hutchings, D.E., 1995. The ontogeny of
cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol. Teratol.
17, 25–30.
Berrendero, F., García-Gil, L., Hernández, M.L., Romero, J., Cebeira, M., de Miguel, R.,
Ramos, J.A., Fernández-Ruiz, J.J., 1998. Localization of mRNA expression and
activation of signal transduction mechanisms for cannabinoid receptor in rat brain
during fetal development. Development 125, 3179–3188.
Blokland, A., Ten Oever, S., van Gorp, D., van Draanen, M., Schmidt, T., Nguyen, E.,
Krugliak, A., Napoletano, A., Keuter, S., Klinkenberg, I., 2012. The use of a test
battery assessing affective behavior in rats: order effects. Behavioral Brain Research
228, 16–21.
Blom, G., 1958. Statistical Estimates and Transformed Beta Variables. John Wiley and
Sons, Inc., New York.
Bradley, B.F., Starkey, N.J., Brown, S.L., Lea, R.W., 2007. Anxiolytic effects of
Lavandula angustifolia odour on the Mongolian gerbil elevated plus maze. J.
Ethnopharmacology 111, 517–525.
67

Burston, J.J., Wiley, J.L., Craig, A.A., Selley, D.E., Sim-Selley, L.J., 2010. Regional
enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats
following repeated Δ9-tetrahydrocannabinol exposure. Br. J. Pharmacol. 161, 103–
112.
Castillo, P.E., Younts, T.J., Chávez, A.E., Hashimotodani, Y., 2012. Endocannabinoid
signaling and synaptic function. Neuron 76, 70–81.
Cha, Y.M., White, A.M., Kuhn, C.M., Wilson, W.A., Swartzwelder, H.S., 2006.
Differential effects of delta9-THC on learning in adolescent and adult rats.
Pharmacol. Biochem. Behav. 83, 448–455.
Chen, J., Paredes, W., Li, J., Smith, D., Lowinson, J., Gardner, E.L., 1990. Δ9tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic
basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as
measured by intracerebral microdialysis. Psychopharmacology (Berl). 102, 156–
162.
Clancy, B., Finlay, B.L., Darlington, R.B., Anand, K.J.S., 2007. Extrapolating brain
development from experimental species to humans. Neurotoxicology 28, 931–937.
Cosquer, B., Galani, R., Kuster, N., Cassel, J.-C., 2005. Whole-body exposure to
2.45GHz electromagnetic fields does not alter anxiety responses in rats: a plus-maze
study including test validation. Behav. Brain Res. 156, 65–74.
Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G.K., Pasquali, R., Pagotto, U.,
2003. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes.
27, 289–301.
Cruz, A.P., Frei, F., Graeff, F.G., 1994. Ethopharmacological analysis of rat behavior on
the elevated plus-maze. Pharmacol. Biochem. Behav. 49, 171–176.
De Felipe, J., Marco, P., Fairén, A., Jones, E.G., 1997. Inhibitory synaptogenesis in
mouse somatosensory cortex. Cereb. Cortex 7, 619–634.
den Boon, F.S., Werkman, T.R., Schaafsma-Zhao, Q., Houthuijs, K., Vitalis, T., Kruse,
C.G., Wadman, W.J., Chameau, P., 2015. Activation of type-1 cannabinoid receptor
shifts the balance between excitation and inhibition towards excitation in layer II/III
pyramidal neurons of the rat prelimbic cortex. Pflügers Arch. 467, 1551–1564.
Devane, W.A., Dysarz, F.A., Johnson, M.R., Melvin, L.S., Howlett, A.C., 1988.
Determination and characterization of a cannabinoid receptor in rat brain. Mol.
Pharmacol. 34, 605–613.
Dobbing, J., Sands, J., 1979. Comparative aspects of the brain growth spurt. Early Hum.
Dev. 3, 79–83.
68

Fellermeier, M., Eisenreich, W., Bacher, A., Zenk, M.H., 2001. Biosynthesis of
cannabinoids. Incorporation experiments with (13)C-labeled glucoses. Eur. J.
Biochem. 268, 1596–1604.
Fleming, C.B., Guttmannova, K., Cambron, C., Rhew, I.C., Oesterle, S., 2016.
Examination of the divergence in trends for adolescent marijuana use and
marijuana-specific risk factors in Washington state. J. Adolesc. Heal. 59, 269–275.
Fontes, M.A., Bolla, K.I., Cunha, P.J., Almeida, P.P., Jungerman, F., Laranjeira, R.R.,
Bressan, R.A., Lacerda, A.L.T., 2011. Cannabis use before age 15 and subsequent
executive functioning. Br. J. Psychiatry 198, 442–447.
Fride, E., 2002. Endocannabinoids in the central nervous system-an overview.
Prostaglandins, Leukot. Essent. Fat. Acids 66, 221–233.
Fried, P., Watkinson, B., James, D., Gray, R., 2002. Current and former marijuana use:
preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ
166, 887–891.
Gaoni, Y., Mechoulam, R., 1964. Isolation, structure, and partial synthesis of an active
constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647.
Garcia, A.M.B., Cardenas, F.P., Morato, S., 2005. Effect of different illumination levels
on rat behavior in the elevated plus-maze. Physiol. Behav. 85, 265–270.
Goonawardena, A. V, Plano, A., Robinson, L., Ross, R., Greig, I., Pertwee, R.G.,
Hampson, R.E., Platt, B., Riedel, G., 2015. Modulation of food consumption and
sleep–wake cycle in mice by the neutral CB1 antagonist ABD459. Behav.
Pharmacol. 26, 289–303.
Gourdet, C., Giombi, K.C., Kosa, K., Wiley, J., Cates, S., 2017. How four U.S. states are
regulating recreational marijuana edibles. Int. J. Drug Policy 43, 83–90.
Grotenhermen, F., 2003. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin.
Pharmacokinet. 42, 327–360.
Haller, J., Bakos, N., Szirmay, M., Ledent, C., Freund, T.F., 2002. The effects of genetic
and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J.
Neurosci. 16, 1395–1398.
Higuera-Matas, A., Ucha, M., Ambrosio, E., 2015. Long-term consequences of perinatal
and adolescent cannabinoid exposure on neural and psychological processes.
Neurosci. Biobehav. Rev. 55, 119–146.
69

Himmler, B.T., Pellis, V.C., Pellis, S.M., 2013. Peering into the dynamics of social
interactions: measuring play fighting in rats. Journal of visual experiments, 71,
4288.
Hogg, S., 1996. A review of the validity and variability of the elevated plus-maze as an
animal model of anxiety. Pharmacol. Biochem. Behav. 54, 21–30.
Hutchings, D.E., Fico, T.A., Banks, A.N., Dick, L.S., Brake, S.C., 1991. Prenatal delta-9tetrahydrocannabinol in the rat: effects on postweaning growth. Neurotoxicol.
Teratol. 13, 245–248.
Huynh, H., Feldt, L.S., 1970. Conditions under which mean square ratios in repeated
measures designs have exact F-distributions. J. Am. Stat. Assoc. 65, 1582–1589.
Järbe, T.U., Sheppard, R., Lamb, R.J., Makriyannis, A., Lin, S., Goutopoulos, A., 1998.
Effects of Δ9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior
in rats. Behav. Pharmacol. 9, 169–174.
Katsidoni, V., Kastellakis, A., Panagis, G., 2013. Biphasic effects of Δ9tetrahydrocannabinol on brain stimulation reward and motor activity. Int. J.
Neuropsychopharmacol. 16, 2273–2284.
Keeley, R.J., Trow, J., Bye, C., McDonald, R.J., 2015. Part II: Strain- and sex-specific
effects of adolescent exposure to THC on adult brain and behaviour: Variants of
learning, anxiety and volumetric estimates. Behav. Brain Res. 288, 132–152.
Ku, K.M., Weir, R.K., Silverman, J.L., Berman, R.F., Bauman, M.D., 2016. Behavioral
Phenotyping of Juvenile Long-Evans and Sprague-Dawley Rats: Implications for
Preclinical Models of Autism Spectrum Disorders. PLoS One 11,58150.
Leo, L.M., Pamplona, F.A., 2014. Elevated plus maze test to assess anxiety-like behavior
in the mouse. Bio-protocol 4, 1211.
Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D., 1996. Sas System for
Mixed Models. SAS Institute, Inc, Cary, NC.
Lupica, C.R., Riegel, A.C., Hoffman, A.F., 2004. Marijuana and cannabinoid regulation
of brain reward circuits. Br. J. Pharmacol. 143, 227–234.
MacCoun, R.J., Mello, M.M., 2015. Half-baked - The retail promotion of marijuana
edibles. N. Engl. J. Med. 372, 989–991.
Manduca, A., Servadio, M., Damsteegt, R., Campolongo, P., Vanderschuren, L.J.,
Trezza, V., 2016. Dopaminergic neurotransmission in the nucleus accumbens
modulates social play behavior in rats. Neuropsychopharmacology 41, 2215–2223.
70

McIlwain, K.L., Merriweather, M.Y., Yuva-Paylor, L.A., Paylor, R., 2001. The use of
behavioral test batteries: effects of training history. Physiol. Behav. 73, 705–717.
Meier, M.H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R.S.E., McDonald,
K., Ward, A., Poulton, R., Moffitt, T.E., 2012. Persistent cannabis users show
neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. U. S.
A. 109, 2657-2664.
Micheva, K.D., Beaulieu, C., 1996. Quantitative aspects of synaptogenesis in the rat
barrel field cortex with special reference to GABA circuitry. J. Comp. Neurol. 373,
340–354.
Miczek, K.A., Barry, H., 1974. Δ9-tetrahydrocannabinol and aggressive behavior in rats.
Behav. Biol. 11, 261–267.
Moore, N.L.T., Greenleaf, A.L.R., Acheson, S.K., Wilson, W.A., Swartzwelder, H.S.,
Kuhn, C.M., 2010. Role of cannabinoid receptor type 1 desensitization in greater
tetrahydrocannabinol impairment of memory in adolescent rats. J. Pharmacol. Exp.
Ther. 335, 294–301.
Newsom, R.J., Kelly, S.J., 2008. Perinatal delta-9-tetrahydrocannabinol exposure disrupts
social and open field behavior in adult male rats. Neurotoxicol. Teratol. 30, 213–
219.
O’Shea, M., Mallet, P.E., 2005. Impaired learning in adulthood following neonatal Δ9THC exposure. Behav. Pharmacol. 16, 455–461.
O’Shea, M., McGregor, I.S., Mallet, P.E., 2006. Repeated cannabinoid exposure during
perinatal, adolescent or early adult ages produces similar longlasting deficits in
object recognition and reduced social interaction in rats. J. Psychopharmacol. 20,
611–621.
Onders, B., Casavant, M.J., Spiller, H.A., Chounthirath, T., Smith, G.A., 2016. Marijuana
exposure among children younger than six years in the United States. Clin. Pediatr.
(Phila). 55, 428–436.
Panksepp, J., Burgdorf, J., 2003. “Laughing” rats and the evolutionary antecedents of
human joy? Physiol. Behav. 79, 533–547.
Pellis, S.M., 2002. Sex differences in play fighting revisited: traditional and
nontraditional mechanisms of sexual differentiation in rats. Arch. Sex. Behav. 31,
17–26.

71

Pellow, S., Chopin, P., File, S.E., Briley, M., 1985. Validation of open:closed arm entries
in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14,
149–167.
Pereira, L.O., da Cunha, I.C., Neto, J.M., Paschoalini, M.A., Faria, M.S., 2005. The
gradient of luminosity between open/enclosed arms, and not the absolute level of
Lux, predicts the behaviour of rats in the plus maze. Behav. Brain Res. 159, 55–61.
Philippot, G., Nyberg, F., Gordh, T., Fredriksson, A., Viberg, H., 2016. Short-term
exposure and long-term consequences of neonatal exposure to Δ9tetrahydrocannabinol (THC) and ibuprofen in mice. Behav. Brain Res. 307, 137–
144.
Pope, H.G., Gruber, A.J., Hudson, J.I., Huestis, M.A., Yurgelun-Todd, D., 2001.
Neuropsychological performance in long-term cannabis users. Arch. Gen.
Psychiatry 58, 909–915.
Quinn, H.R., Matsumoto, I., Callaghan, P.D., Long, L.E., Arnold, J.C., Gunasekaran, N.,
Thompson, M.R., Dawson, B., Mallet, P.E., Kashem, M.A., Matsuda-Matsumoto,
H., Iwazaki, T., McGregor, I.S., 2008. Adolescent rats find repeated Δ9-THC less
aversive than adult rats but display greater residual cognitive deficits and changes in
hippocampal protein expression following exposure. Neuropsychopharmacology 33,
1113–1126.
Realini, N., Viganò, D., Guidali, C., Zamberletti, E., Rubino, T., Parolaro, D., 2011.
Chronic URB597 treatment at adulthood reverted most depressive-like symptoms
induced by adolescent exposure to THC in female rats. Neuropharmacology 60,
235–243.
Richards, J.R., Smith, N.E., Moulin, A.K., 2017. Unintentional cannabis ingestion in
children: A systematic review. J. Pediatr. 190, 142–152.
Rodgers, R.J., Cole, J.C., 1993. Influence of social isolation, gender, strain, and prior
novelty on plus-maze behaviour in mice. Physiol. Behav. 54, 729–736.
Rodgers, R.J., Dalvi, A., 1997. Anxiety, defence and the elevated plus-maze. Neurosci.
Biobehav. Rev. 21, 801–810.
Rodgers, R.J., Haller, J., Holmes, A., Halasz, J., Walton, T.J., Brain, P.F., 1999.
Corticosterone response to the plus-maze: high correlation with risk assessment in
rats and mice. Physiol. Behav. 68, 47–53.
Rodríguez de Fonseca, F., Ramos, J.A., Bonnin, A., Fernández-Ruiz, J.J., 1993. Presence
of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4,
135–138.
72

Rubino, T., Parolaro, D., 2011. Sexually dimorphic effects of cannabinoid compounds on
emotion and cognition. Front. Behav. Neurosci. 5, 64.
Rubino, T., Viganò, D., Realini, N., Guidali, C., Braida, D., Capurro, V., Castiglioni, C.,
Cherubino, F., Romualdi, P., Candeletti, S., Sala, M., Parolaro, D., 2008. Chronic
Δ9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the
emotional profile in adult rats: behavioral and biochemical correlates.
Neuropsychopharmacology 33, 2760–2771.
Rubio, P., Rodríguez de Fonseca, F., Martín-Calderón, J.L., Del Arco, I., Bartolomé, S.,
Villanúa, M.A., Navarro, M., 1998. Maternal exposure to low doses of Δ9tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male
offspring. Pharmacol. Biochem. Behav. 61, 229–238.
Rubio, P., Rodríguez de Fonseca, F., Muñoz, R.M., Ariznavarreta, C., Martín-Calderón,
J.L., Navarro, M., 1995. Long-term behavioral effects of perinatal exposure to Δ9tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis. Life Sci. 56,
2169–2176.
Spear, L.P., 2000. The adolescent brain and age-related behavioral manifestations.
Neurosci. Biobehav. Rev. 24, 417–463.
Substance Abuse and Mental Health Services Administration, 2014. Results from the
2013 National Survey on Drug Use and Health: Summary of National Findings.
Rockville, MD.
Tanda, G., Pontieri, F.E., Di Chiara, G., 1997. Cannabinoid and heroin activation of
mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Science 276, 2048–2050.
Trezza, V., Baarendse, P.J.J., Vanderschuren, L.J.M.J., 2010. The pleasures of play:
pharmacological insights into social reward mechanisms. Trends Pharmacol. Sci. 31,
463–469.
Trezza, V., Campolongo, P., Cassano, T., Macheda, T., Dipasquale, P., Carratù, M.R.,
Gaetani, S., Cuomo, V., 2008a. Effects of perinatal exposure to delta-9tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal
behavioral study in Wistar rats. Psychopharmacology (Berl). 198, 529–537.
Trezza, V., Cuomo, V., Vanderschuren, L.J.M.J., 2008b. Cannabis and the developing
brain: Insights from behavior. Eur. J. Pharmacol. 585, 441–452.
Trezza, V., Damsteegt, R., Manduca, A., Petrosino, S., van Kerkhof, L.W.M.,
Pasterkamp, R.J., Zhou, Y., Campolongo, P., Cuomo, V., Di Marzo, V.,
73

Vanderschuren, L.J.M.J., 2012. Endocannabinoids in amygdala and nucleus
accumbens mediate social play reward in adolescent rats. J. Neurosci. 32, 14899–
14908.
Trezza, V., Vanderschuren, L.J.M.J., 2009. Divergent effects of anandamide transporter
inhibitors with different target selectivity on social play behavior in adolescent rats.
J. Pharmacol. Exp. Ther. 328, 343–350.
Trezza, V., Vanderschuren, L.J.M.J., 2008. Cannabinoid and opioid modulation of social
play behavior in adolescent rats: Differential behavioral mechanisms. Eur.
Neuropsychopharmacol. 18, 519–530.
Ueki, S., Fujiwara, M., Ogawa, N., 1972. Mouse-killing behavior (muricide) induced by
Δ9-tetrahydrocannabinol in the rat. Physiol. Behav. 9, 585–587.
Ullrich, S., Valdez, A.M., 2017. Rocky Mountain high: Preventing cannabis-related
injuries. J. Emerg. Nurs. 43, 78–80.
van Kerkhof, L.W.M., Damsteegt, R., Trezza, V., Voorn, P., Vanderschuren, L.J.M.J.,
2013. Social play behavior in adolescent rats is mediated by functional activity in
medial prefrontal cortex and striatum. Neuropsychopharmacology 38, 1899–1909.
Vanderschuren, L.J.M.J., Achterberg, E.J.M., Trezza, V., 2016. The neurobiology of
social play and its rewarding value in rats. Neurosci. Biobehav. Rev. 70, 86–105.
Vanderschuren, L.J.M.J., Niesink, R.J.M., van Ree, J.M., 1997. The neurobiology of
social play behavior in rats. Neurosci. Biobehav. Rev. 21, 309–326.
Varlinskaya, E.I., Spear, L.P., 2008. Social interactions in adolescent and adult Sprague–
Dawley rats: Impact of social deprivation and test context familiarity. Behav. Brain
Res. 188, 398–405.
Varlinskaya, E.I., Spear, L.P., 2002. Acute effects of ethanol on social behavior of
adolescent and adult rats: role of familiarity of the test situation. Alcohol. Clin. Exp.
Res. 26, 1502–1511.
Varlinskaya, E.I., Spear, L.P., Spear, N.E., 1999. Social behavior and social motivation in
adolescent rats: role of housing conditions and partner’s activity. Physiol. Behav. 67,
475–482.
Wakeford, A.G.P., Flax, S.M., Pomfrey, R.L., Riley, A.L., 2016. Adolescent delta-9tetrahydrocannabinol (THC) exposure fails to affect THC-induced place and taste
conditioning in adult male rats. Pharmacol. Biochem. Behav. 140, 75–81.
Wang, G.S., 2017. Pediatric concerns due to expanded cannabis use: Unintended
consequences of legalization. J. Med. Toxicol. 13, 99–105.
74

Wang, G.S., Roosevelt, G., Le Lait, M.-C., Martinez, E.M., Bucher-Bartelson, B.,
Bronstein, A.C., Heard, K., 2014. Association of unintentional pediatric exposures
with decriminalization of marijuana in the United States. Ann. Emerg. Med. 63,
684–689.
Zamberletti, E., Prini, P., Speziali, S., Gabaglio, M., Solinas, M., Parolaro, D., Rubino,
T., 2012. Gender-dependent behavioral and biochemical effects of adolescent delta9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience 204, 245–
257.
Zeese, K.B., 1999. History of medical marijuana policy in US. Int. J. Drug Policy 10,
319–328.

75

ALTERATIONS IN THE PROTEOMIC PROFILE AND CANONICAL PATHWAYS
IN ADOLESCENT RATS EXPOSED TO ∆9-TETRAHYDROCANNABINOL AS
JUVENILES.
3.1

Introduction

With the legalization of marijuana and related products in several states of USA, an
increase in the marijuana intoxication in children has been reported (Onders et al., 2016;
Wang et al., 2014). The psychoactive component of marijuana is ∆9tetrahydrocannabinol (∆9-THC ; Gaoni and Mechoulam 1964) which targets the type I
cannabinoid receptors (CB1) in brain. The binding of ∆9-THC to CB1 receptors is
responsible for producing various behavioral effects associated with ∆9-THC exposure.
CB1 receptors are involved in a variety of functions in adult brains which are different
from the functions of CB1 receptors in the developing brains of adolescents and
juveniles. This fact is supported by the atypical distribution of CB1 receptors in different
brain areas (Berrendero et al., 1998). During the gestational (Berrendero et al., 1998) or
postnatal period (Romero et al., 1997), CB1 receptors are transiently detected in brain
regions that are not normally associated with CB1 signaling in the adult brain. In
addition, CB1 mRNA and protein decrease gradually and progressively in juvenile and
adolescent brains to finally reach adult levels (Heng et al., 2011). Considering that
juvenile and adolescence are two important stages in terms of brain development,
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exposure to ∆9-THC during any of these periods could have a long-lasting impact on the
functioning of the adult brain and may increase the likelihood of developing psychiatric
disorders (Renard et al., 2014).
Previously, adult studies have addressed the effect of ∆9-THC exposure on the
expression of different parameters such as tyrosine hydroxylase (Bosier et al., 2012),
dopamine receptors (Ginovart et al., 2012), oxytocin receptors (Butovsky et al., 2006),
brain derived neurotropic factor (BDNF; ElBatsh et al., 2012. Butovsky et al., 2005),
glutamate receptor subunits (Fan et al., 2010), the transcription factor cFOS (Marchese et
al., 2008, McCgregor et al., 1998, Miyamoto et al., 1997), orexin receptors (Flores et al.,
2016), the synaptic vesicle protein VAMP2, and the postsynaptic protein PSD95 (Rubino
et al., 2009). However, these studies reported the effects on these parameters in various
brain regions immediately following ∆9-THC exposure. Other studies have addressed the
issue of persistent behavioral and biochemical effects following ∆9-THC exposure in
adolescents or adults (Kasten et al., 2017, Murphy et al., 2017, Weed et al., 2016,
Zamberletti et al., 2016;2015;2014, Fishbein et al., 2012). However, the literature is
limited with respect to addressing the adverse outcome of early onset of cannabis use on
adolescents. We have previously reported that social behavior is altered in adolescents
following repeated juvenile exposure to ∆9-THC (Mohammed et al. 2018). The present
study focused on determining the changes induced by this repeated juvenile exposure to
∆9-THC on the proteomic profile in the amygdala of adolescent rats. The amygdala was
selected because it is one of the brain regions that regulates social behavior (Trezza et al.,
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2013) and because it contains a high density of CB1 receptors (Herkenham et al., 1990),
making it one of the brain regions that is a likely target for ∆9-THC-mediated effects
(Bindukumar et al., 2008, Renard et al., 2014). In this study, label free proteomic analysis
was conducted to determine changes in protein expression followed by further analysis to
determine the pathways and functions most strongly affected by juvenile ∆9-THC
exposure.
3.2
3.2.1

Materials and Method
Chemicals

Δ9-tetrahydrocannabinol was provided by the National Institute on Drug Abuse. All other
chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
3.2.2

Animals

A breeding colony of adult male and female Sprague Dawley rats (CD IGS; Harlan
Laboratories, Indianapolis, IN) were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited facility with temperature control (22
± 2ºC) and with lights on between 0700 and 1900 for a 12-h dark-light cycle. Tap water
and LabDiet rodent chow were freely available during the experimentation. The
procedures used in this project were approved by the Mississippi State University
Institutional Animal Care and Use Committee. From this colony, male and female rat
pups were obtained and the day of birth was considered as PND0. On PND10, rat pups
within the same litter were assigned to different treatment groups. There was always a
representative control animal of the same sex present in each litter to match the ∆9-THCtreated animal.
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3.2.3

Exposure

Beginning on PND10, rats were exposed once a day for 7 days to either corn oil (vehicle)
or 10 mg/kg ∆9-THC by oral gavage at a volume of 0.5 ml/kg. Solutions were delivered
to the back of the throat using a 50-ul tuberculin syringe equipped with a 1-inch 24-gauge
straight intubation needle (Popper and Sons, Inc., New Hyde Park, NY). Rats were
weaned on PND21 and remained in cages undisturbed until PND38.
3.2.4

Proteomic analysis

On the PND38, the whole brain was collected, frozen on a stainless steel plate on top of
dry ice, and stored at -80º C. Three biological replicates of control and ∆9-THC-treated
male rats from different litters were used. Each brain was subjected to coronal sectioning
to obtain 500-micron thick brain slices. Using the rat brain atlas as a reference (Pixons
and Watson 1998), the amygdala was isolated using 1 mm punch and lysed in NP-40
lysis buffer. The protein concentration was measured using a PierceTM BCA protein
assay kit (Thermo Scientific). From each sample, 100 µg of protein was precipitated by
chloroform/methanol extraction. After precipitation, protein digestion was performed by
suspending the pellet in 33 µl of 100 mM Tris-HCl (pH 7.8) containing 6 M urea. The
samples were reduced with 1.6 µl of 200 mM dithiothreitol (DTT) followed by alkylation
with 6.6 µl of 200 mM iodoacetamide (IAA) each for 45 min at room temperature. The
alkylation reaction was quenched by adding 20 µl of 200 mM DTT for 45 min at room
temperature. The urea concentration was reduced by adding 258 µl of milliQ-H20.
Finally, the proteins were digested with trypsin at 1:50 ratio for 18 hr at 37˚C. Protein
digestion was terminated by lowering the pH of each sample to <6 by adding
concentrated acetic acid. The samples were desalted using C18 SepPak columns (Waters,
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USA). These samples were submitted to the University of Arizona Proteomics
Consortium for analysis of samples by using Tandem mass spectrometry coupled to
liquid chromatography (LC-MS/MS).
The LC-MS/MS analysis of trypsin digested protein samples was performed by using
LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, San Jose, CA)
equipped with an Advion nanomate ESI source (Advion, Ithaca, NY). Peptides were
eluted from a C18 pre-column (100-µm id × 2 cm, Thermo Fisher Scientific) onto an
analytical column (75-µm ID × 10 cm, C18, Thermo Fisher Scientific) using a beginning
concentration of 2% solvent B (acetonitrile, 0.1% formic acid) for 5 minutes, then a 2–
7% gradient of solvent B over 5 minutes, followed by a 7-15 % gradient of solvent B
over 50 minutes, a 15-35% gradient of solvent B over 60 minutes, a 35-40% gradient of
solvent B over 28 minutes, a 40-85% gradient of solvent B over 5 minutes, held at 85%
solvent B for 10 minutes, 85-2% gradient of solvent B for 1 minute then held at 2%
solvent B for 16 min. All flow rates were at 400 nl/min. Solvent A consisted of water and
0.1% formic acid. Data dependent scanning was performed by the Xcalibur v 2.1.0
software (Andon et al., 2002) using a survey mass scan at 60,000 resolution in the
Orbitrap analyzer scanning m/z 400–1600, followed by collision-induced dissociation
(CID) tandem mass spectrometry (MS/MS) of the fourteen most intense ions in the linear
ion trap analyzer. Precursor ions were selected by the monoisotopic precursor selection
(MIPS) setting with selection or rejection of ions held to a +/− 10 ppm window. Dynamic
exclusion was set to place any selected m/z on an exclusion list for 45 seconds after a
single MS/MS. All MS/MS spectra were searched against a protein database using
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Thermo Proteome Discoverer 1.3 (Thermo Fisher Scientific, San Jose, CA) using a
Rattus Norveigicus protein database downloaded from Uniprot (http://www.uniprot.org).
Fully tryptic peptides with up to 2 missed cleavage sites were selected. Variable
modifications considered during the search included methionine oxidation (15.995 Da),
and cysteine carbamidomethylation (57.021 Da). Proteins were identified at 99%
confidence with XCorr score cut-offs (Qian et al., 2005) as determined by a reversed
database search.
3.2.5

Data analysis
The proteins and peptide identification results were visualized by using scaffold v

3.6.1 (Proteome software Inc., Portland, OR, USA). Protein identification with a
minimum of two peptides identified with a 0.1% false discovery rate (FDR) were deemed
correct. Significant changes in the protein expression was calculated by using Fisher’s
exact test. Fold changes in the protein expression were calculated using weighted
normalized spectra with 0.2 imputation value.
3.2.6

IPA and gene ontology

For pathway and ontology analysis, the protein list was filtered by applying the LOG2FC
threshold of 0.6 and the Fisher’s exact P-value of 0.08 to ensure the presence of closely
related and biologically significant proteins in the list. Biological interpretation of
identified proteins was performed by DAVID (Database of Annotation, Visualization
and Integrated Discovery). The functional annotation clustering categorizes the
differentially expressed proteins among the controlled vocabulary of Gene Ontology
(GO) in three main categories: Biological process, which describes broad biological goal;
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Molecular function, which describes the task performed by individual gene products; and
Cellular component, which describes the location of molecules inside the cell (Dennis et
al., 2003). In current study, GO terms enriched with differentially expressed protein with
a P-value ≤ 0.05 were selected.
Differentially expressed proteins were also analyzed in Ingenuity Pathway
Analysis (IPA; Qiagen Inc., https://www.qiagenbioinformatics.com) to obtain the
canonical pathways, physiological functions, and networks associated with these proteins.
In the initial analysis for pathways in IPA, only differentially expressed peptides were
included that passed the LOG2FC cutoff 0.6, and Fisher’s exact P-value of 0.05 were
included which identified some biologically relevant pathways. A subsequent analysis
was performed using a Fisher’s exact P-value of 0.08 to include more differentially
expressed proteins. Addition of proteins did not change the enrichment of pathways but
improved the z-scores of pathways that were enriched at P-value of 0.05 (Figure 1).
3.2.7

Quantitative PCR (QPCR)

Total RNA from the amygdala was extracted using the Qiagen RNeasy mini kit
(Germantown, MD), and converted to cDNA by using the Qiagen RT2 cDNA synthesis
kit provided with genomic DNA elimination buffer (Germantown, MD). Pre-designed
gene specific primers, probes (Table 3.1), and Primetime Gene Expression master mix
(Integrated DNA Technology, Coraville, IA) were used to preform real time QPCR. Each
sample was run in triplicate in a final reaction volume of 20 ul according to
manufacturer’s instructions. The thermal cycler conditions were as follows: polymerase
activation- 95º C for 3 min, amplification- 40 cycles of 95º C for 15 sec and 60º C for 1
min. In each experiment, standard curves for the gene of interest and the reference gene
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were made by using a range of cDNA dilutions (1:5-1:1000) and the PCR efficiency
factor was calculated. The threshold Ct value of the gene of interest were normalized
with Ct values of the reference gene and PCR efficiency factor. Normalized Ct values
were used to calculate the fold change from control by using method 2(Ct (control mean) – Ct
(Treatment))

as described by Betancourt et al. (2007). Statistical analysis was conducted on

fold change values by using non-parametric Kruskal-Wallis one-way analysis of variance
to determine the significant treatment effect. The level of statistical significance was set
at P ≤0.05.
Table 3.1
Gene

Primers, probes, and assay names for reference and target genes
Assay name Sequence 5’-3’

name
Actb

Rn.PT.

Primer 1 GGCATAGAGGTCTTTACGGATG

39a.222214

Primer 2 TCACTATCGGCAATGAGCG

838.g

Probe
/5HEX/TCCTGGGTA/ZEN/TGGAATCCTGTGGC/3IAkFQ

Gnai

Rn.PT.58.5

Primer 1 GTCGTTTTCACTCTAGTTCTGAGA

104082

Primer 2 GAGTACCAGCTGAACGATTCG
Probe
/56FAM/CAACCAAAT/ZEN/TACATCCCAACCCAGCA3IABk
FQ
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Table 3.1 (continued)

Gnas

Rn.PT.58.6

Primer 1 CCTTCTCACCATCGCTGTT

088247

Primer 2 CACCATTGTGAAGCAGATGAG
Probe
/56FAM/CCGCCCTCT/ZEN/CCGTTAAACCCATTAA/3IABkF
Q

Gnaq

Rn.PT.58.3

Primer 1 CACAAGCTCTTTATTGCGTCTA

8203772

Primer 2 CACTCTCAAGATCCCATACAAGT
Probe
56FAM/ACACCTTCT/ZEN/CCACATCAACCTCTCGA/3IABkF
Q

Gna13 Rn.PT.58.3
4054555

Primer 1 GCCATCAACTTGTCTCCGT
Primer 2 CACCATCTACAGCAACGTGA
Probe
56FAM/CTTCTCTCG/ZEN/GGCATCTACCAGCAC/3IABkF

3.3

Results and Discussion

This study was designed to determine the persistent changes in amygdaloid proteomic
expression in adolescent rats that occur as a result of repeated exposure to ∆9-THC at
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juvenile stage. The differential expression in proteins due to ∆9-THC exposure was
determined by applying Fisher’s exact P-value threshold (P<=0.08), and LOG2FC
threshold of 0.6. Out of a total of 1169 proteins detected, there were 38 proteins that were
up regulated and 52 proteins that were down regulated due to juvenile ∆9-THC exposure.
Functional clustering of differentially expressed proteins in DAVID revealed that most of
the differentially expressed proteins were part of the cellular components with GO terms
such as synapse, presynaptic membrane, synaptic vesicle and post-synaptic density
significantly enriched (Figure 2) by differentially expressed proteins.
In juveniles, atypical distribution of the CB1 receptors in different brain regions is
responsible for guiding the elongating axons to their targets in order to form a synapse
with the postsynaptic neurons in the target region (Harkany et al., 2008). Large numbers
of differentially expressed synaptic proteins in our study suggest that the improper CB1
activation during juvenile ∆9-THC exposure affected the axonal guidance cue which
disrupted appropriate synapse formation. Altered synapse formation could be the
molecular basis for the social play deficits that we observed in our previous study
(Mohammed et al., 2018).
Table 3.2 lists the total canonical pathways enriched in IPA analysis of differentially
expressed proteins in this study. There are some relevant pathways with positive or
negative activity score are opioid signaling, Gaq signaling, Rho family GTPase, RhoGDI
signaing, and thrombin signaling (Figure 3). The differentially expressed proteins
associated with these pathways are listed in Table 3.3.
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Table 3.2

Canonical pathways predicted using differentially expressed proteins in the
amygdala of adolescent rats (PND38) exposed to either corn oil or 10
mg/kg ∆9-THC during juvenile period (PND10-16).
Canonical pathways

Activity z-score

RhoGDI signaling

Negative

Signaling by Rho family GTPase

Positive

Protein ubiquitination pathway

No pattern

Thrombin signaling

Positive

CXCR4 signaling

Zero

CREB signaling in neurons

Zero

Ephrin signaling

Zero

Ethanol degradation II

No pattern

Noradrenaline and adrenalin

No pattern

degradation
Gaq pathway

Zero

Tec kinase signaling

Zero

G beta-gamma signaling

Zero

IL-B signaling

Zero

Semaphorin signaling in neuron

No pattern

Breast cancer regulation by stathmin

No pattern
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Table 3.2 (continued)
Actin nucleation by ASP-WASP

Zero

complex
Serotonin degradation

No pattern

CCR3 signaling in eosinophile

Zero

Androgen signaling

Zero

Histamine degradation

No pattern

Cardiac hypertrophy signaling

Zero

Oxidative ethanol degradation III

No pattern

Chemokine signaling

Zero

Huntington disease signaling

No pattern

Fatty acid oxidation

No pattern

GM-CSF signaling

Zero

Putriscine degradation

No pattern

Ethanol degradation IV

No pattern

Choline degradation

No pattern

D-Mannose degradation

No pattern

Tryptophan degradation

No pattern

Alpha-adrenergic signaling

Zero

CCR5 signaling in macrophages

Zero

Ephrin receptor signaling

Zero

IL-1 signaling

Zero
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Table 3.2 (continued)
Dopamine degradation

No pattern

G protein signaling mediated by

No pattern

Tubby
Cholestokonin/Gestin mediated

Zero

signaling
Farmaldehyde oxidation II

No pattern

Glutamate dependent acid resistance

No pattern

Oxidative phosphorylation

No pattern

Axonal guidance signaling

No pattern

Neuropathic pain signaling in dorsal

Zero

horn neurons
Glioma signaling

Zero

Role of NFAT in cardiac hypertrophy

Zero

Mechanisms of viral exit from host

No pattern

cell
Rho A signaling

Zero

EIF2 signaling

Negative

Synaptic long term potentiation

Zero

Phospholipase C

Zero

fMLP signaling

Zero

nNOS signaling in neurons

Zero
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Table 3.2 (continued)
Pentose phosphate pathway

No pattern

Opioid signaling

Positive

Phagosome mutation

No pattern

Protein Kinase A signaling

Zero

Lysine degradation II

No pattern

Glutamate degradation III

No pattern

Xenobiotic metabolism

No pattern

Molecular mechanism of cancer

No pattern

Relaxin signaling

Zero

GDP mannose biosynthesis

No pattern

Synaptic long term depression

Zero

Mitochondrial dysfunction

No pattern

GDP-glucose biosynthesis

No pattern

Melatonin signaling

Zero

Role of NFAT regulation in Immune

Zero

response
Glucose and glucose 1 phosphate

No pattern

degradation
Antiproliferative role of somatostatin

Zero

receptor 2
Pentose phosphate pathway

No pattern
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Table 3.2 (continued)
UDP-N-acetyl D-galactosamine

No pattern

biosynthesis
Purine nucleotide de novo

No pattern

biosynthesis
Glycogen degradation

3.3.2

No pattern

Gaq signaling

The CB1 receptors are G-protein coupled receptors and their functioning receptors occurs
by binding to the Gai subunit leading to the inhibition of adenylyl cyclase (See review:
Howlett 2005). This inhibitory action induced by the CB1 receptors is reversed in the
presence of pertussis toxin which blocks the binding of the Gai subunit to the CB1
receptor allowing the synthesis and accumulation of cAMP (Felder et al., 1998). Several
studies have reported that a stimulatory action can be induced by the CB1 receptors and
this occurs through the binding of alternate subunits such as Gas or Gaq depending upon
the relative abundance of each subunit (Bonhaus et al., 1996; Glass and Felder 1997;
Felder et al., 1998; Lauckner et al., 2005). In the current study, we observed an
enrichment of the Gaq signaling pathway which could indicate that the repeated exposure
to ∆9-THC persistently altered the abundance of Gai relative to other subunits. This
hypothesis was tested by measuring the level mRNA expression of the Gai, Gas, Gaq,
and Ga13 subunits using QPCR. The results indicated that there was a 15% fold increase
in the mRNA levels of Gai and Gaq whereas the levels of Gas and Ga13 were unaffected
(Figure 4). Previously, it has been reported that down regulation of the mRNA expression
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for the G protein subunits occurs immediately following repeated exposure to a CB1
agonist (Rubino et al., 1997). Our gene expression data suggest that a reversal of the
effect on the gene expression of G protein subunits occurs after cessation of ∆9-THC
exposure. However, this data may not explain the enrichment of Gaq signaling as seen in
our IPA data because the binding of subunit to receptor may not be correlated to the
amount of mRNA present in tissue (Rubino et al., 1997).
3.3.3

Opioid signaling

In previous studies, it was reported that behavioral and pharmacological effects induced
by ∆9-THC involves co-activation of cannabinoid and opioid receptors (Manharaz et al.,
1999; Ambrosio et al., 1999). This synergistic action of cannabinoid and opioid receptors
is majorly seen with the reward behaviors and antinociception. Absence of either CB1
(Martin et al., 2000) or opioid receptor (Ghozland et al., 2002) abolished the reward
behavior induced by the respective receptor agonist. Chronic exposure to ∆9-THC can
enhance the antinociceptive potency of morphine which is an opioid receptor agonist
(Cichewicz et al., 1999; Welch and Eads, 1999; Smith et al., 1998). ∆9-THC is also
known to produce analgesic effects and one of the major hypotheses behind ∆9-THCinduced analgesia is that it involves synergistic actions of both cannabinoid and opioid
signaling (Welch and Eads, 1999). In addition, it has been reported that CB1 and opioid
receptors are co-localized in amygdala (Novarro et al., 2001) where activation of CB1
receptor is responsible for producing ∆9-THC-induced analgesia (Lee et al., 2011). Thus,
the activation of the CB1 receptor by ∆9-THC can in turn activate opioid signaling.
Based on our data, it appears that this activation of the CB1 receptors during juvenile
brain development leads to a persistent enhancement of opioid signaling which lasts
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through adolescence. One hypothesis behind this ∆9-THC-induced long term alteration in
opioid signaling may be that repeated ∆9-THC exposure in juvenile rats has increased the
opioid receptor density in amygdala as seen in previous study (Cochero et al., 2004). This
may lead to persistent alterations in opioid signaling as seen in our data.
3.3.4

Rho GTPase and thrombin signaling

The Rho family GTPase belong to the Ras superfamily of small peptides. Typically, Rho
peptides are cytoskeleton proteins and involved in the organization of microtubules
(Gunderson et al., 2004) and formation of stress fibers at the cell terminal (Nobes and
Hall 1995) which in turn governs the cell migration and differentiation. In terms of
neuronal development, the members of the Rho family are associated with various
aspects of neural development such as axon formation, neuronal migration, and neurite
outgrowth (Watable-Uchida et al., 2006). Neurite formation and inhibition are two
important phenomena during brain development in order to achieve proper connectivity
between different neurons (Skaper 2005). Several studies reported that activation of Rho
GTPase negatively regulates in the axonal outgrowth (Gu et al., 2013; Harkany et al.,
2008; Ng and Luo 2004; Lehman et al., 1999). Thrombin signaling is also associated
axonal growth. Thrombin signaling occurs through G protein coupled receptors and is
directly related to neurite retraction both during injury and during normal brain
functioning. The addition of Clostridium botulinum C3 exoenzyme, which inhibits Rho,
blocks the thrombin-induced neurite retraction (Jalink et al., 1994) indicating
collaborative action of thrombin signaling and Rho GTPase to control the axonal growth.
As Rho GTPases cycle from the cytoplasmic inactive form to the membrane bound form
where they are active to interact with their targets. RhoGDP-dissociation inhibitors
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(RhoGDI) are regulatory peptides that control Rho signaling by binding to the Rho
proteins in the inactive form (Rho-GDP complex) in cytoplasm thus restricting the
translocation to the membrane where they are activated (Rho-GTP; Robbe et al., 2003).
In our data, there was an inhibition of RhoGDI signaling and activation of Rho GTPase,
and thrombin. Thus, these data are suggesting that the juvenile exposure to ∆9-THC has
persistent effects on neuronal functioning such as axonal formation, and neuronal
migration which are governed by Rho GTPase. Since the juvenile period is a period
where synaptogenesis peaks (Casey et al., 2000) and CB1 receptors were detected in the
elongating axons that would reach the target to form a synapse (Fernandez-Ruiz et al.,
2000), ∆9-THC -mediated activation of CB1 receptor during juvenile period may alter
the synaptogenesis by activating Rho GTPase and thrombin signaling.
3.4

Conclusion

It is well established that the endocannabinoids (EC) and the CB1 receptors are involved
in antinociception and neuronal development. Activation of opioid signaling in our data
may validates a previous hypothesis that antinociceptive action of THC is mediated
through amygdala. Initially, studies only predicted their functions in neural development
based on the presence of CB1 receptors on developing neurons in specific regions
(Romero et al., 1997). Later, involvement of the CB1 receptors in synaptogenesis was
proposed (Fernandez-Ruiz et al., 2000). Our data has provided insight about how the ∆9THC exposure during postnatal ages could persistently affect the neuronal pathways that
are negatively correlated with in axonal migration, or neuritogenesis. As these processes
are eventually involved in synaptogenesis, it is possible that juvenile ∆9-THC exposure
may affect the synaptogenesis in postnatal brain. This is also supported by the functional
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clustering of differentially expressed proteins on DAVID which identified GO terms
related to synapse.

Figure 3.1

Network overlap generated by IPA by list of differentially expressed
proteins at fishers exact P-value of 0.05 (A) and 0.08 (B)
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Figure 3.2

GO term analysis of differentially expressed proteins obtained from
amygdala of adolescent rats (PND38) repeatedly exposed to either corn oil
or 10 mg/kg ∆9-THC during juvenile ages (PND10-16).
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Figure 3.3

Canonical pathways associated with differentially expressed proteins
obtained from amygdala (PND38) of rats exposed repeatedly to either corn
oil or 10 mg/kg ∆9-THC at juvenile ages (PND10-16).
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Table 3.3

List of differentially expressed protein involved in the relevant canonical
pathways shown in figure 3.3

Uniprot Accession

Gene

Entrez Gene name

Regulation

Calcium/calmodulin

Up

Symbol
KCC2A_RAT

CAMK2A

dependent protein
F1M7X3_RAT

CDH3

Cadherine 13

Down

A0A0G2K526_RAT

GNAL

G protein subunit alpha L

Up

G3V8K2_RAT

GNG3

G protein subunit gamma 3

Down

RACK1_RAT

RACK1

Receptor for activated C

Down

kinase 1
A0A0G2K5N6_RAT

ROCK2

Rho associated coiled coil

Up

containing protein
RHOB_RAT

RHOB

Ras containing family

Up

member B
WASF1_RAT

WASF1

Was containing family
member 1
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Up

Table 3.3 (continued)

FILMH0_RAT

SEPT 3

Septin 3

Down

A0A0G2K526_RAT

PRKB

Protein kinase C Beta

Up

PENK_RAT

PENK

Proenkaphalin

Down

Gene expression
1.6

Fold Change from Control

1.4
1.2
1
0.8

GNAiNB

GNAsNB

GNAqNB

GNA13NB

0.6
0.4
0.2
0

Figure 3.4

Change in mRNA expression in amygdala of adolescent rats (PND38)
repeatedly exposed to either corn oil or 10 mg/kg of ∆9-THC during
juvenile ages (PND10-16).
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ALTERATIONS IN CB1-RELATED CANONICAL PATHWAYS DURING SOCIAL
PLAY IN ADOLESCENT RATS REPEATEDLY EXPOSED TO D9TETRAHYDROCANNABINOL AS JUVENILES
4.1

Introduction

Social play is one of the earliest form of interactions with peers that occurs without any
involvement of the mother. Because of this feature, adolescent social play is included
among several important phenomena that are essential for developing normal adult social
behaviors (Pellis and Pellis 2009; van den Berg et al., 1998). The occurrence of social
play is one of the useful biomarkers for neurodevelopment (Blake and McCoy 2015) and
deficits in play performance have been connected to certain neuropsychiatric disorders
(Trezza et al., 2010; Meany and Stewart 1981). Play is a characteristic behavior that starts
during the early stage of life, peaks during the adolescence, and declines at the time of
puberty (Trezza et al., 2010; Martin and Caro et al., 1985). Despite its strong influence in
terms of brain development, our knowledge towards understanding the physiological
mechanism and neural substrates underlying social play is limited (Blake and McCoy
2015; Trezza and Vanderschuren 2008a). Currently, studies are focusing on elucidating
the involvement of the brain endocannabinoid system in mediating social play behavior
through type I Cannabinoid receptors (CB1; Trezza and Vanderschuren 2008b).
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The modulation of social play through endocannabinoid signaling mainly occurs in the
amygdala as demonstrated by Trezza and colleagues (2013). They investigated the effects
of activation of endocannabinoid signaling on social play by administrating the FAAH
inhibitor URB597 that acts as an indirect CB1 agonist and observed that the level of
accumulation of endogenous CB1 ligand (anandamide or AEA) was highest in the
amygdala as compared to other regions such as the hippocampus and the nucleus
acceumbens. Another study focused on the role of CB1 ligands AEA and 2-AG (2arachidonoyl glycerol) in the play behavior. They reported an increase in the social play
activity in rats treated with a dual inhibitor of AEA and 2-AG hydrolysis. This increase in
the social play activities was antagonized by CB1 receptor antagonist (Manduca et al.,
2015).
The CB1 receptors are the primary target of Δ9-tetrahydrocannabinol (∆9-THC; Devane
et al., 1992) which is the main psychoactive component of marijuana (Gaoni and
Mechoulam 1964). The CB1 receptors are involved in a variety of functions related to
neurogenesis (Berrendoro et al., 1998; Romero et al., 1997; Fernandez-Ruiz et al., 2000;
Heng et al., 2011) and some of the forms of neurogenesis, such as neuronal migration and
synaptogenesis, peak during the juvenile period (Markus and Petit 1987). Thus, juvenile
exposure to ∆9-THC could be catastrophic in terms of establishing normal neurological
function which mainly depends on synaptogenesis during the early stages of life (DiazAlanso et al., 2012). When investigating the ∆9-THC-mediated alterations in brain
development, determining the altered canonical pathways in the proteome as it relates to
behavioral function could provide very insightful information. Several studies have
reported immediate or long-term effects of ∆9-THC exposure on social interactions at
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various life stages (Manduce et al., 2015; Trezza et al., 2013; Trezza and Vanderschuren
2008a,b Quinn et al., 2008; Newsome and Kelly 2008; Novarro et al., 1995; Cutler and
Mackintosh 1984; van Ree et al., 1984; Seiber 198; Miczek 1974). However, none of
these studies have investigated the ∆9-THC-mediated changes in the biochemical
pathways related to social play. In our previous study, we reported that adolescent rats
receiving ∆9-THC as juveniles engaged in playful activities for longer duration as
compared to control adolescent rats (Mohammed et al., 2018). We have also determined
the canonical pathways in the proteome altered in adolescents exposed to ∆9-THC as
juveniles in the absence of any behavioral activity. In this study, we determined the
alterations in the canonical pathways in the proteome related directly to ∆9-THCmediated changes in social play.
4.2
4.2.1

Materials and Method
Chemical

Δ9-tetrahydrocannabinol was provided by the National Institute on Drug Abuse. All other
chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
4.2.2

Animals

A breeding colony of adult male and female Sprague Dawley rats (CD IGS; Harlan
Laboratories, Indianapolis, IN) were housed in an Association for Assessment and
Accreditation of Laboratory Animal Care-accredited facility with temperature control (22
± 2°C ) and with lights on between 0700 and 1900 for a 12-h dark-light cycle. Tap water
and LabDiet rodent chow were freely available during the experimentation. The
procedures used in this project were approved by the Mississippi State University
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Institutional Animal Care and Use Committee. From this colony, male and female rat
pups were obtained and the day of birth was considered as PND0. On PND10, rat pups
within the same litter were assigned to different treatment groups. There was always a
representative control animal of the same sex present in each litter to match the ∆9-THCtreated animal.
4.2.3

Exposure

Beginning on PND10, rats were exposed once a day for 7 days to either corn oil (vehicle)
or 10 mg/kg ∆9-THC by oral gavage at a volume of 0.5 ml/kg. Solutions were delivered
to the back of the throat using a 50-ul tuberculin syringe equipped with a 1-inch 24-gauge
straight intubation needle (Popper and Sons, Inc., New Hyde Park, NY). Rats were
weaned on PND21 and categorized into either a behavioral cohort or a non-behavior
cohort. Each cohort consisted of set of rats receiving either vehicle or ∆9-THC.
4.2.4
4.2.4.1

Animal handling
Behavior rats

After weaning on PND21, rats belonging to the behavioral cohort were subjected to
testing in the elevated plus maze (EPM) on PND29 under low illumination followed by
testing for social interactions on PND38 (data presented in Chapter 2). On PND37, these
rats were individually housed for a 24-hour isolation period. A pair of rats of the same
sex and size and belonging to the same treatment group but from different litters were
placed into a novel cage under high illumination (600 lux) and allowed to interact for 10min interval. After social play, the rats were returned to the isolation cage and sacrificed
3-hours later.
109

4.2.4.2

Non-behavior rats

Rats from the non-behavior cohort were handled in the same way as behavior rats with
the exception that they were not subjected to any type of behavior testing. After weaning
on PND21, these rats were individually housed on PND37 for a 24-hour isolation period
and then sacrificed 24-hours following isolation.
4.2.5

Proteomic analysis

On PND38, each rat in both the behavioral and non-behavioral cohorts were sacrificed to
collect the whole brain which was frozen on a stainless steel plate on top of dry ice and
stored at -80°C. Three biological replicates, following exposure conditions, were used.
1) Behavioral Control Rats, which received corn oil and subjected to social play.
2) Behavioral ∆9-THC Rats, which received 10 mg/kg of ∆9-THC and subjected to
social play.
3) Non-behavioral Control Rats, which received corn oil but not subjected to social play.
4) Non-behavioral ∆9-THC Rats, which received ∆9-THC but not subjected to social
play.
Each brain was subjected to coronal sectioning to obtain 500-micron thick brain slices.
Using the rat brain atlas as a reference (Pixons and Watson 1998), the amydgala was
isolated using 1 mm punch and lysed in NP-40 lysis buffer. The protein concentration
was measured using a PierceTM BCA protein assay kit (Thermo Scientific). From each
sample, 100 µg of protein was precipitated by chloroform/methanol extraction. After
precipitation, protein digestion was performed by suspending the pellet in 33 µl of 100
mM Tris-HCl (pH 7.8) containing 6 M urea. The samples were reduced with 1.6 µl of
200 mM dithiothreitol (DTT) followed by alkylation with 6.6 µl of 200 mM
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iodoacetamide (IAA) each for 45 min at room temperature. The alkylation reaction was
quenched by adding 20 µl of 200 mM DTT for 45 min at room temperature. The urea
concentration was reduced by adding 258 µl of milliQ-H20. Finally, the proteins were
digested with trypsin at 1:50 ratio for 18 hr at 37˚C. Protein digestion was terminated by
lowering the pH of each sample to <6 by adding concentrated acetic acid. The samples
were desalted using C18 SepPak columns (Waters, USA). These samples were submitted
to the University of Arizona Proteomics Consortium for Orbitrap LC-MS/MS analysis.
The LC-MS/MS analysis of trypsin digested protein samples was performed by using
LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, San Jose, CA)
equipped with an Advion nanomate ESI source (Advion, Ithaca, NY). Peptides were
eluted from a C18 pre-column (100-µm id × 2 cm, Thermo Fisher Scientific) onto an
analytical column (75-µm ID × 10 cm, C18, Thermo Fisher Scientific) using a beginning
concentration of 2% solvent B (acetonitrile, 0.1% formic acid) for 5 minutes, then a 2–
7% gradient of solvent B over 5 minutes, followed by a 7-15 % gradient of solvent B
over 50 minutes, a 15-35% gradient of solvent B over 60 minutes, a 35-40% gradient of
solvent B over 28 minutes, a 40-85% gradient of solvent B over 5 minutes, held at 85%
solvent B for 10 minutes, 85-2% gradient of solvent B for 1 minute then held at 2%
solvent B for 16 min. All flow rates were at 400 nl/min. Solvent A consisted of water and
0.1% formic acid. Data dependent scanning was performed by the Xcalibur v 2.1.0
software (Andon et al., 2002) using a survey mass scan at 60,000 resolution in the
Orbitrap analyzer scanning m/z 400–1600, followed by collision-induced dissociation
(CID) tandem mass spectrometry (MS/MS) of the fourteen most intense ions in the linear
ion trap analyzer. Precursor ions were selected by the monoisotopic precursor selection
111

(MIPS) setting with selection or rejection of ions held to a +/− 10 ppm window. Dynamic
exclusion was set to place any selected m/z on an exclusion list for 45 seconds after a
single MS/MS. All MS/MS spectra were searched against a protein database using
Thermo Proteome Discoverer 1.3 (Thermo Fisher Scientific, San Jose, CA) using a
Rattus Norveigicus protein database downloaded from Uniprot (http://www.uniprot.org).
Fully tryptic peptides with up to 2 missed cleavage sites were selected. Variable
modifications considered during the search included methionine oxidation (15.995 Da),
and cysteine carbamidomethylation (57.021 Da). Proteins were identified at 99%
confidence with XCorr score cut-offs (Qian et al., 2005) as determined by a reversed
database search.
4.2.6

Data analysis

The protein and peptide identification results were visualized with Scaffold v 3.6.1
(Proteome Software Inc., Portland, OR, USA). Protein identifications with a minimum of
two peptides identified at 0.1% peptide false discovery rate (FDR) were deemed correct.
Significant changes in protein expression were identified by Fisher’s exact test. Fold
changes in protein expression were calculated using weighted normalized spectra with
0.5 imputation value.
The different comparisons were as follows:
A) Control behavior verses ∆9-THC behavior
B) ∆9-THC non-behavior verses ∆9-THC behavior
C) Control non-behavior verses Control behavior
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4.2.7

IPA and gene ontology

For pathway and ontology analysis, the protein list was filtered by applying the log2fc
threshold of 0.6 and the Fisher’s exact P-value of 0.05. Biological interpretation of
identified proteins was performed by DAVID (Database of Annotation, Visualization
and Integrated Discovery). The functional annotation clustering categorizes the
differentially expressed proteins among the controlled vocabulary of Gene Ontology
(GO) in three main categories: Biological process, which describes broad biological goal;
Molecular function, which describes the task performed by individual gene products; and
Cellular component, which describes the location of molecules inside the cell (Dennis et
al., 2003). In current study, GO terms enriched with differentially expressed protein with
a P-value ≤ 0.05 were selected.
Differentially expressed proteins were also analyzed in Ingenuity Pathway Analysis (IPA;
Qiagen Inc., https://www.qiagenbioinformatics.com) to obtain canonical pathways,
physiological functions, and networks associated with these proteins.
4.2.8

Quantitative PCR (QPCR)

Total RNA from the amygdala was extracted using the Qiagen RNeasy mini kit
(Germantown, MD) and converted to cDNA by using the Qiagen RT2 cDNA synthesis
kit provided with genomic DNA elimination buffer (Germantown, MD). Pre-designed
gene specific primers, probes (Table 4.1) and Primetime Gene Expression Mastermix
(Integrated DNA Technology, Coraville, IA) were used to perform real time QPCR. Each
sample was run in triplicate in a final reaction volume of 20 ul according to
manufacturer’s instructions. The thermal cycler conditions were as follows: polymerase
activation- 95C for 3 min, amplification- 40 cycles of 95C for 15 sec and 60C for 1 min.
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In each experiment, standard curves for the gene of interest and the reference gene were
made by using a range of cDNA dilutions (1:5-1:1000) and the PCR efficiency factor was
calculated. The threshold Ct value of the gene of interest were normalized with Ct values
of the reference gene, and PCR efficiency factor. Normalized Ct values were used to
calculate the fold change from control by using method 2(Ct (Control mean) – Ct (Treatment)) as
described by Betancourt et al. (2007). Statistical analysis was conducted on the fold
change values by using a non-parametric Kruskal-Wallis one way analysis of variance
test to determine the significant treatment effect. The level of significance was set at p
≤0.05.
Table 4.1

Gene

Primers, probes, and assay names for reference and target genes

Assay name

Sequence 5’-3’

Rn.PT.

Primer 1 GGCATAGAGGTCTTTACGGATG

39a.222214838.

Primer 2 TCACTATCGGCAATGAGCG

g

Probe

name
Actb

/5HEX/TCCTGGGTA/ZEN/TGGAATCCTGTGGC/3IAkFQ

Gnai

Rn.PT.58.5104

Primer 1 GTCGTTTTCACTCTAGTTCTGAGA

082

Primer 2 GAGTACCAGCTGAACGATTCG
Probe
/56FAM/CAACCAAAT/ZEN/TACATCCCAACCCAGCA3IABk
FQ
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Table 4.1 (continued)

Gnas

Rn.PT.58.6088

Primer 1 CCTTCTCACCATCGCTGTT

247

Primer 2 CACCATTGTGAAGCAGATGAG
Probe
/56FAM/CCGCCCTCT/ZEN/CCGTTAAACCCATTAA/3IABkF
Q

Gnaq

Rn.PT.58.3820

Primer 1 CACAAGCTCTTTATTGCGTCTA

3772

Primer 2 CACTCTCAAGATCCCATACAAGT
Probe
56FAM/ACACCTTCT/ZEN/CCACATCAACCTCTCGA/3IABkF
Q

Gna1

Rn.PT.58.3405

Primer 1 GCCATCAACTTGTCTCCGT

3

4555

Primer 2 CACCATCTACAGCAACGTGA
Probe
56FAM/CTTCTCTCG/ZEN/GGCATCTACCAGCAC/3IABkF

4.3

Results and Discussion

In Chapter 2, we determined the effects of juvenile treatment with ∆9-THC on social
behavior in adolescent rats. In Chapter 3, we determined the changes in amygdaloid
proteomic expression and the associated canonical pathways in non-behavioral
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adolescent rats treated with ∆9-THC as juveniles. Our lab has previously compared the
changes in amygdaloid proteomic expression and the associated canonical pathways in
control rats undergoing behavioral testing with non-behavioral control rats (Alugubelly et
al., 2018). In this chapter, we extended those studies to determine the relationship
between the changes in proteomic expression and the altered social behavior. This was
done by comparing the differentially expressed proteins in the amygdala and the
associated canonical pathways in (1) Control behavioral rats and ∆9-THC-treated
behavioral rats and (2) ∆9-THC-treated behavioral rats and ∆9-THC-treated nonbehavioral rats.
4.3.1

Control behavioral verses ∆9-THC-treated behavioral comparison

In this analysis, protein validation using Scaffold identified 51 proteins that were
differentially expressed. DAVID analysis revealed that GO term related to the biological
process such as microtubule cytoskeleton organization and cell adhesion, and the cellular
component such as cell leading edge (Figure 4.1). These GO terms are involved in axonal
guidance (Dent and Gertler 2003), contact between axonal growth cone and target cell
(Brose 1999) or neurite growth (Rehaine and Madox 2015).
Further analysis of these differentially expressed proteins using IPA revealed the
enrichment of canonical pathways listed in table 1. Figure 4.2 indicates several important
pathways based on the number of differentially expressed proteins involved, and the
relevance of these pathways in terms of brain development. Some of these pathways are
possibly related to CB1 signaling such as protein kinase A, CREB signaling, and cAMP
signaling, phospholipase C and calcium signaling. Other pathways such as thrombin
signaling and opioid signaling are important in terms of brain development or social play
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(Figure 1B). Thrombin signaling, a key pathway involved in the neurite retraction in
developing brains (Jalink 1994), and opioid signaling were inhibited in the ∆9-THCtreated behavioral rats as compared to the vehicle treated behavioral rats. Interestingly,
opioid signaling was activated in ∆9-THC-treated non-behavioral rats compared to
vehicle-treated behavioral rats, whereas it was inhibited in ∆9-THC-treated behavioral
rats. This suggests that juvenile ∆9-THC exposure may have affected the opioids
(receptors or peptides) that would cause altered binding and/or activation of opioid
signaling during adolescence.
Thrombin signaling in neurons is activated when cells are going through several
biological processes such as neurite retraction (Jalink et al., 1994), or apoptosis (Denovan
et al., 1997). Other studies reported that thrombin is produced in the brain following the
brain injury which may lead to break down of blood brain barrier (Xi et al., 2003). In our
study, thrombin signaling was enriched in ∆9-THC-treated behavior rats compared to ∆9THC-treated non-behavior rats but was not enriched in vehicle-treated behavior rats
compared to vehicle-treated non-behavioral rats. This suggests that the juvenile ∆9-THC
exposure caused some damage to the brain, including neurons in the amygdala causing
them to synthesize thrombin. However, inhibition of thrombin signaling in ∆9-THCtreated behavior rats, may indicate an adaptive response elicited by amygdala neurons
following social play.
In Chapter 3 we reported the mRNA expression of G protein subunits in non-behavior
adolescent rats receiving ∆9-THC as juveniles. Because social play activates the CB1 and
opioid signaling which share the common G protein mediated mechanism of activation
(Trezza and Vanderschuren 2008), we were interested to measure the abundance of G
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protein subunit mRNA in ∆9-THC-treated behavior rats. There was a 6% increase in the
Gnai subunit, but Gaq mRNA was reduced by 13% relative to control (Figure 1C). Down
regulation of Gaq may indicate the reversal effect of social play on signaling because in
Chapter 3, we reported the up regulation of Gaq in ∆9-THC-treated non-behavior rats.
Down regulation of Gaq mRNA may be associated with inhibition of calcium signaling
and phospholipase C (PLC) signaling (Figure 4.2). In previous study, it was reported that
CB1 agonist-mediated activation of PLC and Ca++ signaling occurs through binding of
Gaq subunit to CB1 receptor (Lauckner et al., 2005). Since PLC is an enzyme involved in
the biosynthesis of the CB1 ligand 2-arachidonoyl glycerol (2-AG; Kano et al., 2009), it
can be hypothesized that developmental ∆9-THC exposure may cause long term
alterations in 2-AG synthesis.
In previous studies, it has been demonstrated that CB1 signaling can have an
enhancing effect on social play behavior (Trezza et al., 2008 a,b; Trezza et al., 2013;
Manduce et al., 2015). However, there are also studies that report the opposite effect of
CB1 activation on social play behavior (O’Shea et al., 2006; Schneider and Koch 2005).
This disparity was addressed by Trezza and Vanderscuren (2008a,b) who, considering the
high reward value of social play in rats, demonstrated that a cross-talk between
cannabinoid and opioid receptors exists and this is responsible for the ∆9-THC-induced
and/or CB1 activation-mediated enhancement of social play behavior. In the present
study, we observed inhibition of opioid signaling in the ∆9-THC-treated rats when they
were subjected to social play. A possible explanation may be the inhibition of related
pathways such as CREB signaling and PKA signaling. Both of these pathways are
inhibited due to down regulation of cAMP (Koh et al., 1997). CREB is a transcriptional
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factor which is phosphorylated by PKA to its active form. The activation or inhibition of
CREB in different brain regions can control different types of behaviors including
anxiety and reward behaviors (Review: Carlezon et al., 2005). It has been demonstrated
that microinjection of ∆9-THC into the amygdala inhibits CREB activation leading to an
anxiogenic response in rats (Rubino et al., 2008). It was also reported that CREB activity
is inhibited in the presence of opioid agonist, mainly because of the inhibitory action of
opioid receptor on cAMP (Guitart et al., 1992). On the other hand, opioid antagonist
activates CREB by releasing the tonic inhibition of opioid receptor on cAMP (ShawLutchman et al., 2002). In present study, inhibition of cAMP, CREB, and PKA signaling
in ∆9-THC treated rats is in agreement with previous studies.

Table 4.2

List of canonical pathways obtained from differentially expressed proteins
in amygdala of adolescent rats receiving either corn oil or 10 mg/kg ∆9THC during juvenile ages (PND10-16). Tissue was extracted on PND38,
either 3-hours following play
Canonical pathways

Activity z-score

Protein Kinase A

Negative

Sirtuin signaling pathway

Negative

Thrombin signaling

Negative

CREB signaling in neurons

Negative

Calcium signaling

Negative

GM-SCF signaling

Negative

Ephrine receptor signaling

Negative

B cell receptor signaling

Negative

Integrin signaling

Positive

Phospholipase C

Negative

cAMP mediated signaling

Negative
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Table 4.3 (continued)
iCOS-iCOSL signaling in T helper

Negative

cells
Neuropathic pain signaling in dorsal

Negative

horn neuron
Negative

Synaptic long term potentiation

Negative

Glioma signaling

Negative

Melanin signaling

Negative

GNRH signaling

Negative

PKCB in T lymphocytes

Negative

PI3K in B lymphocytes

Negative

GOTERM
GOTERM_M
_BP_DIR
F_DIRECT GOTERM_CC_DIRECT
ECT

Chemokine signaling

cell adhesion
microtubule cytoskeleton organization
microtubule organizing center organization
anchored component of membrane
cell leading edge
cell junction
mitochondrial outer membrane
proteasome complex
mitochondrial inner membrane
mitochondrial outer membrane
mitochondrial respiratory chain complex I
metal ion binding
4 iron, 4 sulfur cluster binding
2 iron, 2 sulfur cluster binding
NADH dehydrogenase (ubiquinone) activity
0
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GO term analysis of differentially expressed proteins obtained from
amygdala tissue of behavioral rats repeatedly exposed to either corn oil or
10 mg/kg ∆9-THCduring juvenile ages (PND10-16). Tissue was extracted
3-hours following social play on PND38.
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Figure 4.2

Relevant canonical pathways obtained from IPA analysis of differentially
expressed proteins obtained from amygdala tissue of behavioral rats
repeatedly exposed to either corn oil of 10 mg/kg ∆9-THC during juvenile
ages (PND10-16). Tissue was extracted 3-hours following social play on
PND 38.

Table 4.3

Differentially expressed proteins involved in the relevant canonical
pathways shown in Figure 4.2.
Uniport Accession

Gene

Entrez Gene Name

Regulation

Calcium/calmodulin

Down

Symbol
KCC4_RAT

CAMK4

dependent protein
kinase IV
KCC2A_RAT

CAMK2A

Calcium/calmodulin

Down

dependent protein
kinase II
FILUE2_RAT

CAMK2B

Calcium/calmodulin
dependent protein
kinase II beta
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Down

Table 4.3 (continued)
KCC2D_RAT

CAMK2D

Calcium/calmodulin

Down

dependent protein
kinase II
A0A0G2K319_RAT

DUSP3

Dual specificity

Down

phosphatase
GNA13_RAT

GNA13

G protein subunit

Down

alpha13
M0R809_RAT

GNG4

G protein subunit

Up

gamma 4
GRB2_RAT

GRB2

Growth factor receptor

Down

G3V9Y1_RAT

MYH10

Myosine heavy chain
10

Up

A0A0G2JSW0_RAT

MYL2A

Myosine light chain
12A

Up

PDE18_RAT

PDE18

Phosphodiesterase 18

Up

PPR18_RAT

PPP1R1B

Up

RACK1_RAT

RACK1

Protein phosphatase 1
regulatory inhibition
subunit
Receptor for activated
C kinase 1
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Up

Fold Change from Control

*

1.2
1

GNAiB

0.8
0.6

GNAsB

GNAqB

GNA13B

*

0.4
0.2
0

Figure 4.3

4.3.2

Gene Expression

Relative change in mRNA expression of G protein subunits in amygdala of
behavioral rats repeatedly exposed to either corn oil or 10 mg/kg of ∆9THC during juvenile ages (PND10-16). Tissue was extracted 3-hours
following social play on PND38.

∆9-THC-treated behavioral versus ∆9-THC-treated non-behavioral
comparison

In this analysis, protein validation using Scaffold identified 64 proteins that were up
regulated and 67 proteins that were down regulated. Functional clustering of these
differentially expressed proteins was performed by using DAVID which identified GO
term related to cellular component such as cell junction, cell-cell adherence and synapse
(Figure 4.4).
Further analysis of these differentially expressed proteins using IPA revealed enrichment
of canonical pathways listed in Table 4. The canonical pathways such as thrombin
signaling and opioid signaling PKA, cAMP and CREB signaling are the same pathways
that we observed to be altered in our previous experimental comparison discussed above.
The differentially expressed proteins associated with these pathways are listed in table 5.
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Additional pathways significantly enriched included dopamine degradation and dopamine
DARPP32 feedback in cAMP signaling (Figure 4.5). The differentially expressed
proteins involved in these pathways are listed in Table 5.
The dopamine degradation pathway involved only monoamine oxidase (MAO) A and B
from our list of differentially expressed proteins. Down regulation of MAO may indicate
the decrease in dopamine degradation as this enzyme is responsible for dopamine
degradation. This finding is in agreement with previous studies that reported an increase
in the neuronal firing in dopamine producing brain regions such as the ventral tegmental
area and the substantia nigra (Renard et al., 2017; Wu et al., 2000) and an increase in the
dopamine release (Oleson et al., 2012; Chen et al., 1990) following ∆9-THC exposure.
However, an increase in the dopamine metabolites has also been observed following oral
exposure to ∆9-THC (Novorro et al., 1993). This contradicts our findings in that we
observed a down regulation of MAO which may not be correlated to increase in the
dopamine metabolites. Dopaminergic neurotransmission is modulated by the retrograde
action of CB1 receptors on GABA neurons which inhibits dopamine synthesis (Solinas et
al., 2006). ∆9-THC-mediated activation of the CB1 receptors may have been responsible
for ∆9-THC-mediated increase in dopamine levels observed by Novorro et al. (1993). It
is also possible that the ∆9-THC-mediated increase in dopamine was due to the inhibitory
action of ∆9-THC on MAO levels (Fisar 2010).
DARPP-32 is a protein phosphatase inhibitor mainly present in the dopaminergic neurons
(Fernandez et al., 2006) and present in the brain regions which are enriched with
dopamine innervations including the amygdala (Yger and Girault 2011). DARPP-32 is
activated due to the stimulatory action of dopamine receptor (D1) on cAMP and PKA,
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which phosphorylates DARPP-32 on Thr34 site. Thr34 phosphorylation eventually
causes inhibition of CREB (Fernandez et al., 2006). Another study reported cyclin
dependent kinase (cdk5) can phosphorylate DARPP-32 on Thr75 site which is
responsible for inhibition of PKA (Bibb et al., 1999). Another study reported that
DARPP-32 feedback in cAMP signaling pathway is activated when there is an interaction
between opioid and dopaminergic neurotransmission (Mahajan et al., 2009). Also, the
dual activation of opioid and dopamine receptor is associated with increase in the social
play activity (Niesink and van Ree 1989). Therefore, inhibition of cAMP, CREB, PKA,
opioid, dopamine degradation and DARPP-32 feedback signaling pathways found in our
study may indicate that these pathways are inter related and play a role in mediating
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GO term analysis of differentially expressed proteins obtained from
amygdala of adolescent rats repeatedly exposed to only ∆9-THC during
juvenile ages (PND10-16). Tissue was extracted on PND38, either 3-hours
following play (behavior ∆9-THC) or without being subjected to play (nonbehavior ∆9-THC)
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Table 4.4

List of canonical pathways obtained from differentially expressed proteins
in amygdala of adolescent rats receiving only 10 mg/kg ∆9-THC during
juvenile ages. Tissue was extracted on PND38, either 3-hours following
play (behavior ∆9-THC) or without being subjected to play (non-behavior
∆9-THC).
Canonical pathways

Activity z-score

CREB signaling in neurons

Negative

Melatonin signaling

Negative

GNRH signaling

Negative

Thrombin signaling

Negative

Opioid signaling

Negative

Synaptic long term potentiation

Negative

CXCR4 signaling

Negative

CCR3 signaling in eosinophils

Negative

fMLP signaling in neutrophils

Negative

Androgen signaling

Negative

Chemokine signaling

Negative

Corticotrophin releasing hormone
signaling
Protein kinase A signaling

Negative

GPCR signaling

Negative

Xenobiotic metabolism signaling

Negative

GPCR mediated nutrient sensing in
enteroendocrine cells
IL-B signaling

Negative

UVC-induced MAPK signaling

Negative

Neuropathic pain signaling in
dorsal horn neurons
Gaq signaling

Negative

G beta gamma signaling

Negative
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Negative

Negative

Negative

Table 4.4 (continued)
Phospholipase C signaling

Negative

P2Y purigenic receptor signaling

Negative

UVB induced MAPK signaling

Negative

FC epsin RI signaling

Negative

Dopamine DRPP-32 feedback in

Negative

cAMP signaling
Synaptic long term depression

Negative

GM-CSF signaling

Negative

Tryptophan degradation

Negative

Renin Angiotensin signaling

Negative

cAMP mediated signaling

Negative

NRF2-mediated oxidative stress

Negative

Neuroglin signaling

Negative

LPS-mediated MAPK

Negative

Ca induced T lymphocyte apoptosis

Negative

ErbB signaling

Negative

Cholestokonin mediated signaling

Negative

Thrombopiotin signaling

Negative

eNOS signaling

Negative

PPAR/RXR-alpha activation

Negative

PI3K signaling in B lymphocytes

Negative
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Table 4.4 (continued)
Huntington disease signaling

Negative

CDK5 signaling

Negative

Endothein signaling

Negative

GP6 signaling

Negative

Adrenomeduline signaling

Negative

P7056K signaling

Negative

Ca signaling

Negative

Aldosterone signaling in epithelial

Negative

cells

Figure 4.5

Relevant canonical pathways obtained from differentially expressed
proteins in amygdala of adolescent rats receiving oly 10 mg/kg ∆9THCduring juvenile ages (PND10-16). Tissue was extracted on PND38,
either 3-hours following play (behavior ∆9-THC) or without being
subjected to play (non-behavior ∆9-THC).
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Table 4.5

Differentially expressed proteins involved in relevant canonical pathways
shown in figure 4.5
Uniprot Accession

Gene

Entrez Gene Name

Regulation

Aldehyde

Down

Symbol
FILN88_RAT

ALDH2

dehydrogenase
G3V9G1_RAT

ADCYC

Adenylyl cyclase 5

Down

A0A0G2K7E5_RAT

CACNA2D1

Calcium voltage-

Down

gated channel
auxiliary subunit
alpha2delta 1
KCC4_RAT

CAMK4

Calcium/calmoduline

Down

dependent protein
kinase IV
FILUE2_RAT

CAMk2B

Calcium/calmodulin

Down

dependent protein
kinase II beta
KCC2D_RAT

CAMK2D

Calcium/calmodulin

Down

dependent protein
kinase II delta
GNAS2_RAT

GNAS

GNAS complex
locus
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Up

Table 4.5 (continued)
M0R809_RAT

GNG4

G protein gamma

Down

subunit
FILNE4_RAT

GRIA2

Glutamate

Up

ionotrophic receptor
AMPA subunit 2
MAP2K1_RAT

MAP2K1

Mitogen activated

Down

protein kinase kinase
1
FILP57_RAT

MAP2K4

Mitogen actiavated

Up

protein kinase kinase
II
KPCA_RAT

PRKCA

Protein kinase C

Down

alpha
A0A0G2KSQ0_RAT

PRKCB

Protein kinase C beta

Down

KPCG_RAT

PRKCG

Protein kinase C

Down

gamma
RACK1_RAT

RACK1

Receptor for

Up

activated C kinase
S12AS_RAT

SLC12AS

Solute carrier family
12 member 5
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Down

Table 4.5 (continued)
FILX13_RAT

PDE10A

Phosphodiesterase

Down

10A
CDK5_RAT

CDKS

Cyclin dependent

Down

kinase 5
FILV89_RAT

RAPGAP

Rap1 GTPase

Down

AOFA_RAT

MAOA

Monoamine oxidase

Down

A

4.3.3

Control behavior and control non-behavior comparison

In this analysis, protein validation using Scaffold identified 38 proteins that were up
regulated and 64 proteins that were down regulated. Functional clustering of these
differentially expressed proteins by using DAVID revealed that there was enrichment of
molecular functions such as axonogenesis and positive regulation of axon elongation and
enrichment of cellular components related to the synapse such as postsynaptic density
and synaptic vesicles (Figure 4.6).
Further analysis of these differentially expressed proteins using IPA revealed enrichment
of canonical pathways listed in table 6. Figure 3B indicates the most relevant pathways
which are discussed in details. These pathways include opioid signaling, PKA signaling,
cAMP signaling and dopamine degradation. Several studies reported the enhancing effect
of opioid signaling on social play behavior (Trezza and Vanderschuren 2008 a,b;
Vanderschuren et al., 1995 a,b; Beatty et al., 1982). As activation of opioid signaling in
amygdala is mainly responsible for translating learned reward into motivation This
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results in increased appetitive and/or consummatory behaviors towards that reward
(Mahler and Berridge 2009). As play is a natural reward in rats, activation of opioid
signaling in amygdala of behavioral rats was not surprising. The opioid signaling mainly
occurs by binding of Gai subunits to opioid receptor causing inhibition of adenylyl
cyclase enzyme. This causes decrease in cAMP and PKA signaling (Davis et al., 2003).
Both cAMP and PKA signaling are decreased in our data.
The activation of opioid signaling was reversed in ∆9-THC-treated behavioral rats as
discussed in the previous sections. This may indicate that juvenile ∆9-THC exposure
altered opioid signaling in the brain that would alter the motivation for reward. However,
despite the inhibition of opioid signaling, ∆9-THC-treated rats engaged in social play for
more amount of time compared to controls as reported in chapter 2. Therefore, it can be
hypothesized that juvenile ∆9-THC exposure causes functional changes in opioid
signaling that would alter its activation during reward behaviors. Same pattern was
observed for dopamine degradation pathway in both vehicle-treated and ∆9-THC-treated
behavioral rats. In both comparisons, dopamine degradation pathway was enriched
because of downregulation of MAO enzyme. This indicates inhibitory action of social
play on dopamine degradation in amygdala. Previous studies have reported the enhancing
effect of dopamine release on social play (Trezza et al., 2008; Peills et al., 1993; Neisink
and van Ree 1989; Beatty et al., 1984). However, it is still need to be confirmed if the
reduction in the MAO activity following social play can cause the accumulation of
dopamine in amygdala and dopamine producing regions such as ventral tegmental area
and striatum.
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Figure 4.6

GO term analysis of differentially expressed proteins obtained from
amygdala tissue of rats repeatedly exposed to corn oil during juvenile ages
(PND10-16). Tissue was extracted on PND38, either 3-hours following
play (behavior controls) or without being subjected to play (non-behavior
controls).

Table 4.6

List of canonical pathways obtained from differentially expressed proteins
in amygdala of adolescent rats exposed to corn oil during juvenile ages
(PND10-16). Tissue was extracted on PND38, either 3-hours following
play (behavior control) or without being subjected to play (non-behavior
control).
Canonical pathways

Activity z-score

Mitochondrial dysfunction

No pattern

Sirbutin signaling

Positive
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Table 4.6 (continued)
Glycogen degradation

Zero

Oxidative phosphorylation

Negative

Dopamine receptor signaling

Zero

Melatonin degradation

Zero

GDP-glucose biosynthesis

Zero

Glucose phosphatase degradation

Zero

Glycogen degradation

Zero

Protein kinase A signaling

Negative

Cardiac beta adrenergic signaling

Negative

Phenylalanine degradation

Zero

Serotonin receptor signaling

No pattern

Tryptophan degradation

Zero

Leukocyte extravasation

Zero

Dopamine degradation

Zero

Gai signaling

Zero

Noradrenaline degradation

Zero

Protein ubiquitnation

Zero

cAMP signaling

Negative

Relaxin signaling

Zero

Gaq signaling

Zero

Opioid signaling

Positive
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Table 4.6 (continued)

Figure 4.7

NADH repair

Zero

tRNA splicing

Zero

Serotonin degradation

Zero

Melatonin degradation

Zero

GPCR signaling

Zero

EIF2 signaling

Zero

Gustation pathway

Zero

Semaphorin signaling

No pattern

Relevant canonical pathways obtained from differentially expressed
proteins obtained from amygdala of adolescent rats repeatedly exposed to
only corn oil during juvenile ages (PND10-16). Tissue was extracted on
PND38, either 3-hours following play (behavior controls) or without being
subjected to play (non-behavior controls).
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Table 4.7

List of differentially expressed proteins involved in canonical pathways
listed in figure 4.

Uniprot Accession

Gene

Entrez Gene

Regulation

Symbol

Name

D3ZFQ8_RAT

CYC 1

Cytochrome c1

Down

NDUA9_RAT

NDUFA9

NADH

Down

Ubiquinone
NDUAA_RAT

NDUAF10

NADH

down

Ubiquinone
D4A0T0_RAT

NDUFB10

NADH

Down

Ubiquinone
NDUS2_RAT

NDUSF2

NADH

Down

Ubiquinone
UCR1_RAT

UQCRFS1

Ubiquinol

Down

cytochrome c
G3V9G1_RAT

ADCYC5

Adenylyl cyclase

Down

5
AOFA_RAT

MAOA

Monoamine

Down

oxidase A
AOFB_RAT

MAOB

Monoamine
oxidase B
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Down

Table 4.7 (continued)
A0A0G2KKB98_RAT

GSK3B

Glycogen

Up

synthetase kinase
3 beta
FILX13_RAT

PDE10A

Phosphodiesterase

Down

10A
PDE1B_RAT

PDE1B

Phosphodiesterase

Down

1B
PP1R7_RAT

PPP1R7

Protein

Down

phosphatase 1
regulatory subnit
7
RACK1_RAT

RACK1

Receptor for

Down

activated C kinase
1
A0A0G2K5N6_RAT

ROCK2

Rho associated

Up

coiled coil
containing protein
FILV89_RAT

RAP1GAP

Rap1GTPase
activating
proteins
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Down

Table 4.7 (continued)
D3ZWGZ_RAT

RGS7

Receptor for G

Down

protein signaling
7
A0A0G2KB98_RAT

CLTA

Clathrin light

Down

chain A

4.4

Conclusion

This study evaluated the social play-mediated enrichment of canonical pathways in the
amygdala and how these pathways are altered by developmental ∆9-THC exposure. We
report that developmental ∆9-THC exposure alters normal opioid signaling during social
play behavior as evidenced by the fact that engaging in social play by control rats
activates opioid signaling, whereas prior exposure to ∆9-THC inhibits the social playinduced opioid signaling in rats. This is the most significant finding in this study because
opioid signaling is mainly activated during the reward behaviors. We also found
inhibition of thrombin signaling in ∆9-THC-treated behavioral rats. As thrombin
signaling is activated in response to neuronal damage, enrichment of thrombin signaling
in ∆9-THC treated rats may indicate a response of the neurons to the damage induced by
developmental ∆9-THC exposure.
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CONCLUSION
There are numerous studies addressing the cognitive deficits in adults resulting from
marijuana use during adolescence (Vadhan et al., 2017; Forti et al., 2014; Cass et al.,
2014; Saez et al., 2014; Hajos et al., 2007) or gestation (Huizink 2014; Berghuis et al,
2007; Huizink et al., 2006). Given the increased popularity of ingesting marijuana edibles
that has recently developed, this research investigated the persistent behavioral deficits
and relevant signaling pathways that are altered following juvenile exposure to the
psychoactive component of marijuana ∆9-THC. ∆9-THC is considered to be the main
component responsible for producing the cognitive deficits associated with marijuana
(D’Souza et al., 2005). The primary target of ∆9-THC in the brain is stimulation of the
type I cannabinoid receptor (CB1) which is also involved in various aspects of brain
development (Watson et al., 2008). Thus, the persistent neurological deficits associated
with developmental marijuana exposure may be due to overstimulation of the CB1
receptor (Wilkinson et al., 2015) such that the normal progression of the brain
development is disrupted.
Neurite outgrowth and axonal migration are two important steps in brain development
that shape the connectivity of the brain by establishing proper synaptic connections
across the regions (Fernandez-Ruiz et al., 2000). The CB1 receptor is consistently present
in neurons undergoing these processes and is crucially important in the establishment of
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the appropriate connections (Gaffari et al., 2012; Fernandez-Ruiz et al., 2000). During
development, the acquisition of new behavioral skills depends upon the neuronal
processes such as dendritic growth, the number of synapses and size of synapses in the
brain (Dagwood et al., 1985). As juvenile period is associated with sharp increase in the
number of synapses (Markaus and Petit 1987), over activation of CB1 receptor during
this period can profoundly affect the acquisition of behavioral skills.
In our behavior data, we did not observe any direct effect of juvenile ∆9-THC exposure
on anxiety in adolescent rats in the elevated plus maze (EPM). One possible reason have
could been the age at which the testing was conducted. Adolescence is a period
characteristically linked with increased risk taking (Steinbern 2007). This natural
tendency to take risks during adolescence may have simply increased the overall level of
exploration and this decreased the ability to measure any increases or decreases in the
level of anxiety during testing. We did observe significant differences in the social
interaction test in adolescent rats exposed to ∆9-THC as juveniles. The most significant
parameters affected involved increased levels of play behavior by the ∆9-THC-treated
rats. A possible neurobiological explanation for this increased play behavior could be that
the ∆9-THC exposure induced persistent changes that disrupted the inhibitory and
excitatory balance in the brain. Activation of the CB1 receptor on the gammaaminobutyric acid (GABA) neurons inhibits the release of GABA which reduces the
inhibitory action of GABA in the brain. This ‘dis-inhibition’ has been reported to be
enhanced by ∆9-THC treatment in rats (Radhakrishnan et al., 2015).
Our proteomic data identified the cellular pathways associated with ∆9-THC exposure
and/or social play behavior in amygdala neurons. Thrombin signaling was the most
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relevant pathway affected in ∆9-THC rats. Thrombin signaling in neurons is mainly
responsible for growth cone collapse and neurite retraction (Jalink et al., 1994) which
impairs the navigation of the axon and prevents it from reaching its target synapse
(Harkany et al., 2008). In our data, enrichment of thrombin signaling was detected in ∆9THC-treated behavioral rats and non-behavioral rats but was not detected in vehicletreated rats which indicates that a long-term effect of repeated ∆9-THC ingestion during
the juvenile period is altered thrombin signaling in neurons of the amygdala. As thrombin
signaling in neurons is involved in neurite retraction (Jalink et al., 1994), is activated
following brain injury (Vaughan et al., 1995) and is associated with neuronal death (Choi
et al., 2003), the enrichment of thrombin signaling in ∆9-THC-treated rats in the current
study may indicate that juvenile ∆9-THC exposure has altered one or more of these
processes that thrombin signaling is linked to.
In addition, opioid signaling was enhanced in ∆9-THC-treated non-behavioral rats as
compared to control non-behavioral rats but was inhibited in ∆9-THC-treated behavioral
rats as compared to control behavioral rats. The different effects of ∆9-THC exposure on
opioid signaling induced by the presence or absence of social behavior may suggest
altered competitive binding of the cannabinoid and/or opioid receptors to G proteins
subunits. The cannabinoid and opioid receptors share a common G protein subunit and
dual activation of both cannabinoid and opioid receptors during social play (Trezza and
Vanderschuren 2008) in ∆9-THC-treated rats may have attenuated the binding of Gai
subunit to opioid receptor as previously reported (Rios et al., 2006). Since opioid
signaling is mainly associated with nociception and repeated ∆9-THC treatment reduces
the response to painful stimuli even long after treatment ceases (Martin et al., 2004;
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Caroline et al., 2000), this suggests that repeated ∆9-THC dampens the response of
opioid signaling to stimuli. Our results agree with this premise in that introduction of a
behavioral challenge resulted in the inhibition of opioid signaling in the amygdala of rats
treated with ∆9-THC.
Overall, this study investigated the persistent effects of oral ∆9-THC exposure during the
juvenile period and included the behavioral alterations observed and the cellular
pathways that were either activated or inhibited in the amygdala of those exposed rats
once they reached adolescence. This research has limitations in that it only tested the
persistent alterations in behaviors related to anxiety and social interactions in response to
exposure to ∆9-THC. First, our EPM data suggest an increase in locomotor activity in
∆9-THC-treated rats. Future studies should focus on validating the effects on ∆9-THC on
locomotor activity using a more appropriate behavioral test specific for measuring this
type of behavior. Secondly, we observed ∆9-THC-mediated effects on thrombin signaling
in the amygdala neurons. Both thrombin signaling (Harkany et al., 2008) and the CB1
receptor (Fernandez-Ruiz et al., 2000) are involved in the migration of axons to target
neurons in order to form a synapse. Therefore, future studies should also include
investigation of the potential alterations in synaptic density throughout the entire brain
following oral juvenile exposure to ∆9-THC. Thirdly, we observed that in ∆9-THCtreated behavior rats, there is an alteration in opioid signaling. This may suggest
alterations in the binding affinity of G protein subunits to the opioid receptor in the
amygdala. Future studies should investigate the binding affinity of G protein subunits to
the opioid receptor in animals previously treated with ∆9-THC by administering a
challenge that would activate opioid receptors.
149

While the popularity of edible marijuana products is increasing in the United States, the
data obtained in our study may provide an insight to the increasing popularity of
marijuana and related products in the United States. Our data has clearly established a
link between repeated juvenile ∆9-THC exposure and deficits in social behaviors during
adolescence. This effect of ∆9-THC on the developing brain in juveniles may challenge
to the public’s attitude to support the popularity of marijuana products. As addressed by
previous studies, the child friendly packaging of marijuana edibles and the lack of
limitations on the maximum content of ∆9-THC in a single edible are major threats to the
children. Our data suggest that consumption of edibles by juveniles may be catastrophic
in terms of the acquisition of skills which are necessary for meeting the challenges in
future life. The results of this study also strongly suggest that care should be taken when
popularizing marijuana edible products in the media so that children will not misinterpret
marijuana as being safe for them to ingest.
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Table A.1

List of differentially expressed proteins obtained from vehicle or D9-THC
treated non-behavior rats

Uniprot Accession

Fishers exact P-value

TBA3_RAT
G3P_RAT
MBP_RAT
ATPB_RAT
ACON_RAT
ALBU_RAT
DYN1_RAT
1433Z_RAT
F1MA36_RAT
VATB2_RAT
Q6T487_RAT
KCC2A_RAT
DPYL4_RAT
CALR_RAT

0.015
0.022
0.029
0.035
0.072
0.019
0.048
0.065
0.0019
0.047
0.0015
0.0035
0.04
0.059

0.378511623
0.584962501
0.584962501
0.485426827
0.485426827
-0.152003093
0.485426827
0.485426827
-0.321928095
0.485426827
-0.514573173
0.765534746
0.678071905
-0.321928095

G3V741_RAT
D4A0F5_RAT
A0A0G2K5Q0_RAT
G3V9Y1_RAT

0.039
0.059
0.047
0.022

-0.321928095
-0.321928095
0.765534746
-0.514573173

Q6IMZ3_RAT
DCE2_RAT
D3ZFQ8_RAT
PP1R7_RAT
F1LX07_RAT
ROA1_RAT
F1LMH0_RAT
F1LN88_RAT

0.0055
0.026
0.039
0.064
0.061
0.056
0.057
0.072

1.201633861
1
-0.514573173
-0.514573173
-0.514573173
-0.514573173
-0.736965594
1.070389328

HPCL4_RAT
A0A0G2K079_RAT
NDUAA_RAT
A0A0A0MY13_RAT

0.017
0.032
0.023
0.032

-0.736965594
1.485426827
-1
1.378511623

RHOB_RAT
F1LPG3_RAT
Q5RK08_RAT
WASF1_RAT

0.043
0.0018
0.061
0.061

1
2.744161096
1.263034406
1.263034406
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LOG2FC

Table A.1 (continued)
A0A0G2JUT1_RAT

0.066

-0.736965594

RACK1_RAT
D3ZFX4_RAT

0.0039
0.011

-1.321928095
4.087462841

ADHX_RAT

0.038

-1

LIN7A_RAT

0.035

1.925999419

DC1I1_RAT

0.071

1.632268215

B0BNL2_RAT
PRS6B_RAT

0.038
0.022

-1.321928095
2.201633861

REEP5_RAT

0.0046

-1.736965594

D4AB17_RAT

0.0092

2.137503524

PENK_RAT
DC1L1_RAT

0.032
0.0099

-1
-2.321928095

F1M1Y0_RAT

0.035

2.070389328

USO1_RAT

0.0014

-4.321928095

A0A0G2K459_RAT

0.078

-3.321928095

F1M7X3_RAT
G3V8K2_RAT

0.0099
0.066

-2.321928095
-1

G3V8R2_RAT

0.0053

-2.321928095

YKT6_RAT

0.033

3.807354922

B4F7C7_RAT

0.0056

-3.836501268

G3V940_RAT
Q5EBD0_RAT

0.064
0.019

1.432959407
-1.321928095

6PGL_RAT

0.022

2.201633861

PSB3_RAT

0.021

-3.473931188

A0A0G2K3V4_RAT

0.071

-1

PSB1_RAT
A0A0G2KA27_RAT

0.0083
0.035

2.432959407
2.070389328

F1M013_RAT

0.041

-3.321928095

F1LM19_RAT

0.038

-1.321928095

TMM35_RAT

0.078

-3.321928095

A0A0G2K5N6_RAT

0.019

4

A0A0G2K6T9_RAT

0.018

-1.736965594

Q6P3V9_RAT

0.0099

-1.736965594

SFXN5_RAT

0.025

-1.321928095

PPM1E_RAT
UBA5_RAT

0.021
0.058

-3.64385619
-1.736965594
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Table A.1 (continued)
AGAP2_RAT

0.033

3.700439718

A0A0G2JY03_RAT
RCN2_RAT

0.033
0.0051

-1.736965594
2.5360529

Q5RJN0_RAT

0.043

-1.321928095

RD23B_RAT

0.033

-1.736965594

MPI_RAT

0.078

-3.321928095

NTF2_RAT
PRIO_RAT

0.033
0.041

-1.736965594
-3.321928095

PSMD1_RAT

0.056

1.925999419

D4A5X7_RAT

0.058

-1.321928095

PHYIP_RAT
D3ZT36_RAT

0.023
0.033

-1.321928095
3.700439718

ZWINT_RAT

0.078

-3.321928095

CHRD1_RAT

0.033

3.700439718

AL7A1_RAT

0.055

3.584962501

TXTP_RAT
G3V7Q6_RAT

0.033
0.055

-1.736965594
3.584962501

G3V7U4_RAT

0.071

-1.321928095

G3V7I8_RAT

0.055

3.584962501

O88321_RAT

0.055

3.584962501

PSB2_RAT
D3ZRM9_RAT

0.078
0.041

-3.321928095
-3.473931188

M0RC57_RAT

0.011

4.087462841

A0A0G2JT00_RAT

0.055

3.584962501

sp|P62243|RS8_RAT

0.041

-3.321928095

G3V914_RAT
G3V912_RAT

0.043
0.033

-1.736965594
3.700439718

PA2G4_RAT

0.011

-3.836501268

A0A0G2K724_RAT

0.021

-3.473931188

B2RYS8_RAT

0.078

-3.321928095

RLA1_RAT

0.078

-3.321928095

RUVB1_RAT

0.055

3.584962501

B1H2A2_RAT

0.078

-3.321928095

RLA0_RAT

0.021

-3.473931188

D3Z9G9_RAT
D3ZM33_RAT

0.041
0.078

-3.321928095
-3.321928095
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Table A.1 (continued)
A0A0G2K526_RAT

0.056

2.201633861

M0R7P0_RAT
Q505I9_RAT

0.078
0.078

-3.321928095
-3.321928095

Table A.2

List of differentially expressed proteins obtained from vehicle or D9-THC
treated behavior rats

Uniprot Accession
KCC2A_RAT
D4A8U7_RAT
F1LUE2_RAT [5]
NDUS1_RAT
Q5XIH3_RAT
D3ZA84_RAT
CALX_RAT
A0A0G2K9J2_RAT
KCC2D_RAT
G3V9Y1_RAT
VDAC2_RAT
NFM_RAT
LSAMP_RAT
A0A0G2JZM8_RAT
UCRI_RAT
Q5M7T6_RAT
PALM_RAT
RACK1_RAT
PPR1B_RAT
GRB2_RAT
A0A0G2K8V2_RAT
(+2)
PDE1B_RAT
CALB1_RAT
A0A0G2JSW0_RAT
[2]
A0A0G2K261_RAT
ACYP2_RAT
A0A0G2K3I9_RAT
RAP2B_RAT [2]
G3V7L6_RAT (+1)

Fishers Exact P-Value
0.001
0.00074
0.0074
0.034
0.0082
0.014
0.042
0.018
0.013
0.0091
0.0032
0.0076
0.039
0.025
0.023
0.00042
0.0093
0.023
0.02
0.04
0.046

LOG2FC
0.736965594
-1
0.736965594
0.584962501
1
-1
0.678071905
-1
0.736965594
0.925999419
1.070389328
1.201633861
-1
-1
1.137503524
1.736965594
1.378511623
1.137503524
1.5360529
1.736965594
1.321928095

0.011
0.0068
0.044

2.201633861
1.632268215
1.137503524

0.034
0.034
0.012
0.02
0.03

3.584962501
3.584962501
2.321928095
1.5360529
1.736965594
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Table A.2 (continued)
FUBP1_RAT
NDUV2_RAT
ERR1_RAT
I6L9G6_RAT
AGAP2_RAT
G3V7Q6_RAT
NDUS2_RAT
KCC4_RAT
ACBP_RAT [2]
A0A0H2UI10_RAT
B2GUY4_RAT (+1)
A0A0G2K0P8_RAT
Q6PDW1_RAT
D3Z955_RAT
TOM34_RAT
sp|K22E_HUMAN|
M0R809_RAT
G3V964_RAT
M0R4B6_RAT (+1)
A0A0G2KAZ7_RAT
GNA13_RAT
G3V8H3_RAT

Table A.3

0.01
0.025
0.0018
0.033
0.036
0.019
0.0056
0.02
0.02
0.036
0.034
0.034
0.036
0.02
0.036
0.0014
0.034
0.0061
0.018
0.019
0.03
0.036

3.906890596
1.378511623
4.321928095
1.321928095
3.473931188
3.700439718
4.087462841
1.736965594
3.836501268
-3.64385619
3.584962501
3.584962501
3.473931188
3.836501268
-3.64385619
2.321928095
3.584962501
4.058893689
2.070389328
3.700439718
1.736965594
-3.64385619

List of differentially expressed proteins obtained from D9-THC treated
behavior or non-behavior rats

Uniprot Accession
D4ABN3_RAT
GPM6A_RAT
D3ZDU5_RAT
PCLO_RAT
PGRC1_RAT
NFM_RAT
A0A0G2JZH8_RAT
A0A0G2JUT1_RAT
PCYOX_RAT
F1LRZ7_RAT
D4A435_RAT
CX6C2_RAT

Fishers Exact P-Values
0.0043
0.0017
0.03
0.038
0.016
0.0082
0.0087
0.049
0.0052
0.041
0.021
0.024
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LOG2FC
0.678071905
0.925999419
0.765534746
1
0.925999419
1.263034406
1.321928095
0.925999419
1.5360529
2.03562391
1.722466024
3.700439718

Table A.3 (continued)
THIC_RAT
A0A0G2KAW4_RAT
RACK1_RAT
B4F774_RAT
CSKI1_RAT
F1LV13_RAT
B0BNL2_RAT
ELOB_RAT
RTCB_RAT
A0A0G2K926_RAT
sp|P62909|RS3_RAT
B1WC34_RAT
F1LP57_RAT
PSA2_RAT
Q5EBD0_RAT
CDS2_RAT
D3ZWA8_RAT
SCAM1_RAT
D4A781_RAT
PPM1E_RAT
LASP1_RAT
B4F7C7_RAT
A0A0G2K6T9_RAT
G3V6L9_RAT
DNJA2_RAT
M0R735_RAT
A0A0G2K0V8_RAT
A0A0H2UHF6_RAT
D3ZDC0_RAT
CSRP1_RAT
ZWINT_RAT
ACYP2_RAT
A0A0G2JZB8_RAT
A0A0G2K7W7_RAT
FUBP1_RAT
Q6P3V9_RAT
SCN2B_RAT
MPI_RAT
A0A0G2K0P8_RAT
PRRT2_RAT
UK114_RAT
LYPA2_RAT

0.002
0.0052
0.013
0.021
0.025
0.041
0.014
0.014
0.014
0.0004
0.014
0.0055
0.015
0.024
0.014
0.0089
0.0052
0.025
0.0044
0.0013
0.041
0.0078
0.0052
0.014
0.0089
0.0024
0.024
0.025
0.0044
0.014
0.043
0.043
0.014
0.024
0.014
0.025
0.024
0.024
0.043
0.014
0.041
0.043
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2.560714954
2.232660757
1.321928095
1.632268215
1.378511623
1.5360529
1.5360529
3.906890596
3.906890596
4.584962501
3.906890596
2
1.847996907
1.584962501
1.5360529
2.10433666
2.201633861
2.292781749
4.169925001
4.392317423
1.722466024
4
2.232660757
3.906890596
2.10433666
4.247927513
3.700439718
1.847996907
4.169925001
3.906890596
3.584962501
3.584962501
3.906890596
3.700439718
3.807354922
1.722466024
3.700439718
3.700439718
3.584962501
3.906890596
2.137503524
3.459431619

Table A.3 (continued)
SGT1_RAT
PRIO_RAT
F1LNE4_RAT
NPTX1_RAT
AP1M1_RAT
M0R907_RAT
sp|P21531|RL3_RAT
A0A0G2JVS2_RAT
M0R809_RAT
RAB4B_RAT

Table A.4

0.043
0.014
0.037
0.024
0.043
0.043
0.0078
0.043
0.043
0.00022

3.459431619
3.906890596
1.378511623
3.700439718
3.459431619
3.459431619
4
3.459431619
3.459431619
4.700439718

List of differentially expressed proteins obtained from D9-THC treated
behavior or non-behavior rats

Uniprot Accession
F1LNK0_RAT
M0R8M9_RAT
D4A8U7_RAT
Q499Q4_RAT
RUFY3_RAT
ERR1_RAT
G3V6L4_RAT
D3ZHY9_RAT
A0A0G2K4X8_RAT
A0A0G2JSZ5_RAT
PACS1_RAT
Q5U2P5_RAT
I6L9G6_RAT
Q5M9H7_RAT
G3V6T1_RAT
LASP1_RAT
PCYOX_RAT
Q5U2S7_RAT
PRS7_RAT
A0A0G2KB98_RAT
ELOB_RAT
RTCB_RAT
LYAG_RAT

Fishers Exact PValues
0.033
0.022
0.0016
0.036
0.048
0.0056
0.029
0.0051
0.02
0.024
0.0077
0.048
0.047
0.032
0.047
0.0094
0.0038
0.047
0.03
0.016
0.047
0.042
0.016
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LOG2FC
0.584962501
0.584962501
1.263034406
1.201633861
1.070389328
4.321928095
1.5360529
1.765534746
1.584962501
1.432959407
2.5360529
1.807354922
1.722466024
1.847996907
2.070389328
4.247927513
2.40599236
1.925999419
2.201633861
4.087462841
1.925999419
3.700439718
4.087462841

Table A.4 (continued)
M0R735_RAT
A0A0G2K5N6_RAT
A0A0G2K7W7_RAT
CSRP1_RAT
PSMD1_RAT
O88321_RAT
PSB1_RAT
B5DFN4_RAT
D3ZWA8_RAT
PPM1H_RAT
RCN2_RAT
D3ZPR0_RAT
D3Z955_RAT
A0A0G2JT00_RAT
D3Z981_RAT

0.047
0.0056
0.032
0.042
0.047
0.042
0.047
0.042
0.026
0.042
0.03
0.042
0.042
0.026
0.016
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2.070389328
4.321928095
1.925999419
3.700439718
2.070389328
3.700439718
2.070389328
3.807354922
3.906890596
3.807354922
2.201633861
3.700439718
3.807354922
3.906890596
4.087462841

